For my patients with schizoaffective disorder, one treatment comes to mind:



the first and only approved acute treatment for schizoaffective disorder'



J. AVERY, MD Dept. of Psychiatry

INVEGA[®] is an atypical antipsychotic agent indicated for the

- > acute and maintenance treatment of schizophrenia¹
- > acute treatment of schizoaffective disorder as monotherapy¹
- > acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants^{*1}



www.INVEGA.com

*In 2 clinical studies, the most commonly used mood stabilizers were valproate and lithium. The most commonly used antidepressants were SSRIs and SNRIs. Use of MAOIs was excluded.¹

For more information, including study designs and clinical data, please contact your Janssen® representative.

IMPORTANT SAFETY INFORMATION FOR INVEGA®

WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis

WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® (paliperidone) is not approved for the treatment of patients with dementia-related psychosis.

Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone, which is a metabolite of risperidone, therefore paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in INVEGA®.

Cerebrovascular Adverse Events (CAEs): CAEs, including fatalities and stroke, have been reported in elderly patients with dementia-related psychosis taking oral risperidone in clinical trials. The incidence of CAEs with risperidone was significantly higher than with placebo. INVEGA® is not approved for the treatment of patients with dementia-related psychosis.

Approved for the treatment of patients with dementia-related psychosis. **Neuroleptic Malignant Syndrome (NMS):** NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including paliperidone. Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and close medical monitoring, and treatment of any concomitant serious medical problems.

medical problems. QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. Avoid the use of drugs that also increase QT interval and in patients with risk factors for prolonged QT interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias. Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval. **Tardive Dyskinesia (TD):** TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose, but can develop after relatively brief treatment at low doses. Elderly women

Reference: 1. INVEGA[®] (paliperidone) [Prescribing Information]. Titusville, NJ., Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Please see brief summary of full Prescribing Information for INVEGA® on adjacent page.

patients appeared to be at increased risk for TD, although it is impossible to predict which patients will develop the syndrome. Prescribing should be consistent with the need to minimize the risk of TD. Discontinue drug if clinically appropriate. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.
Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including INVEGA®. Patients starting treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Some patients require continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
Hyperprolactinemia: As with other drugs that antagonize dopamine D₂ receptors, INVEGA® elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to risperidone, which is associated with higher levels of prolactin elevation than other antipsychotic agents.
Orthostatic Hypotension and Syncope: INVEGA® may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period. Monitoring should be used with caution in patients with known cardiovascular disease, cerebrovascular disease or conditions that would predispose patients to hypotension.
Leukopenia, Neutropenia and Agranulocytosis have been reported with backing and in some patients.

disease or conditions that would predispose patients to hypotension. **Leukopenia, Neutropenia and Agranulocytosis** have been reported with antipsychotics, including paliperidone. Patients with a history of clinically significant low white blood cell count (WBC) or drug-induced leukopenia/neutropenia should have frequent complete blood cell counts during the first few months of therapy. At the first sign of a decline in WBC and in the absence of other causative factors, discontinuation of INVEGA® should be considered. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs or signs of infection and treated promptly if such symptoms or signs or signs of infection and treated promptly for the WBC followed until recovery. **Potential for Cognitive and Motor Impairment:** Somnolence, sedation, and dizziness were reported as adverse reactions in subjects treated with INVEGA®. INVEGA® has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that INVEGA® does not affect them adversely, and should use caution when operating machinery. **Seizures:** INVEGA® should be used cautiously in patients with a history of

not affect them adversely, and should use caution when operating machinery. **Seizures:** INVEGA® should be used cautiously in patients with a history of seizures or with conditions that potentially lower seizure threshold. **Suicide:** The possibility of suicide attempt is inherent in schizophrenia. Close supervision of high-risk patients should accompany drug therapy. **Maintenance Treatment:** Physicians who elect to use INVEGA® for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient. **Commonly Observed Adverse Reactions:** The most commonly observed adverse reactions in clinical trials occurring at an incidence of ≥5% and at least 2 times placebo were: schizophrenia—extrapyramidal symptoms, tachycardia, and akathisia; schizoaffective disorder— extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis.



INVEGA®

(paliperidone) Extended-Release Tablets

Brief Summary

BEFORE PRESCRIBING INVEGA®, PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions]

INVEGA® (paliperidone) Extended-Release Tablets are indicated for the acute and maintenance treatment of schizophrenia *[see Clinical Studies (14) in full PI*].

CONTRAINDICATIONS

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. INVEGA® (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in INVEGA®.

WARNINGS AND PRECAUTIONS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA® (paliperidone) is not approved for the treatment of dementia-related psychosis [see Boxed Warning].

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients With Dementia-Related Psychosis: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. INVEGA® was not marketed at the time these studies were performed. INVEGA® is not approved for the treatment of patients with dementia-related psychosis [see also Boxed Warning and Warnings and Precautions].

Neuroleptic Malignant Syndrome: A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

INVEGA® (paliperidone) Extended-Release Tablets

The effects of paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia. In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% Cl: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate-release was more than twice the exposure observed with the maximum recommended 12 mg dose of INVEGA® (C_{max} ss = 113 ng/mL and 45 ng/mL, respectively, when administered with a standard breakfast). In this same study, a 4 mg dose of the immediate-release oral paliperidone, for which C_{max} ss = 35 ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% Cl: 3.6; 10.1) on day 2 at 1.5 hours post-dose. None of the subjects had a change exceeding 60 msec or a QTcLD exceeding 500 msec at any time during this study.

For the three fixed-dose efficacy studies in subjects with schizophrenia, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the INVEGA® 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec). No subject receiving INVEGA® had a UTcLD exceeding 500 msec at any time in any of these three studies.

Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, INVEGA® should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA®, drug discontinuation should be considered. However, some patients may require treatment with INVEGA® despite the presence of the syndrome.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA®. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because INVEGA® was not marketed at the time these studies were performed, it is not known if INVEGA® is associated with this increased risk. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Hyperprolactinemia: Like other drugs that antagonize dopamine D_2 receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats [see Nonclinical Toxicology (13.1) in full PI]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive. Potential for Gastrointestinal Obstruction: Because the INVEGA® tablet is non-deformable and does not appreciably change in shape in the gastrointestinal tract, INVEGA® should ordinarily not be administered to patients with pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic, for example: esophageal motility disorders, small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel's diverticulum). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of drugs in non-deformable controlled-release formulations. Because of the controlled-release design of the tablet, INVEGA® should only be used in patients who are able to swallow the tablet whole [see Dosage and Administration (2.3) and Patient Counseling Information (17.8) in full PI]

A decrease in transit time, e.g., as seen with diarrhea, would be expected to decrease bioavailability and an increase in transit time, e.g., as seen with gastrointestinal neuropathy, diabetic gastroparesis, or other causes, would be expected to increase bioavailability. These changes in bioavailability are more likely when the changes in transit time occur in the upper GI tract.

Orthostatic Hypotension and Syncope: Paliperidone can induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. In pooled results of the three placebo-controlled, 6-week, fixed-dose trials in subjects with schizophrenia, syncope was reported in 0.8% (7/850) of subjects treated with INVEGA® (3 mg, 6 mg, 9 mg, 12 mg) compared to 0.3% (1/355) of subjects treated with placebo. INVEGA® should be used with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.

Leukopenia, Neutropenia, and Agranulocytosis: Class Effect: In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including INVEGA®. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of INVEGA® should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm³) should discontinue INVEGA® and have their WBC followed until recovery

Potential for Cognitive and Motor Impairment: Somnolence was reported in subjects treated with INVEGA® [see Adverse Reactions]. Antipsychotics. including INVEGA®, have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that paliperidone therapy does not adversely affect them.

Seizures: During premarketing clinical trials in subjects with schizophrenia (the three placebo-controlled, 6-week, fixed-dose studies and a study conducted in elderly schizophrenic subjects), seizures occurred in 0.22% of subjects treated with INVEGA® (3 mg, 6 mg, 9 mg, 12 mg) and 0.25% of subjects treated with placebo. Like other antipsychotic drugs, INVEGA® should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. INVEGA® and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Suicide: The possibility of suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for INVEGA® should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. Priapism: Drugs with alpha-adrenergic blocking effects have been reported to induce priapism. Priapism has been reported with INVEGA® during postmarketing surveillance. Severe priapism may require surgical intervention.

Thrombotic Thrombocytopenic Purpura (TTP): No cases of TTP were observed during clinical studies with paliperidone. Although cases of TTP have been reported in association with risperidone administration, the relationship to risperidone therapy is unknown.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing $INVEGA^{\circledast}$ to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Antiemetic Effect: An antiemetic effect was observed in preclinical studies with paliperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reve's syndrome, and brain tumor

Use in Patients with Concomitant Illness: Clinical experience with INVEGA® in patients with certain concomitant illnesses is limited [see Clinical Pharmacology (12.3) in full PI].

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

INVEGA® has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical trials. Because of the risk of orthostatic hypotension with INVEGA®, caution should be observed in patients with known cardiovascular disease [see Warnings and Precautions].

Monitoring: Laboratory Tests: No specific laboratory tests are recommended. **ADVERSE REACTIONS**

- The following are discussed in more detail in other sections of the labeling:
- Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions]
- · Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions]
- Neuroleptic malignant syndrome [see Warnings and Precautions]
- QT prolongation [see Warnings and Precautions]
- Tardive dyskinesia [see Warnings and Precautions]
- Hyperglycemia and diabetes mellitus [see Warnings and Precautions]
- Hyperprolactinemia [see Warnings and Precautions]
 - Potential for Gastrointestinal Obstruction [see Warnings and Precautions]
 - Orthostatic hypotension and syncope [see Warnings and Precautions]
 - Leukopenia, neutropenia, and agranulocytosis [see Warnings and Precautions]
 - Potential for cognitive and motor impairment [see Warnings and Precautions]
 - Seizures [see Warnings and Precautions]
 - Dysphagia [see Warnings and Precautions]
 - Suicide [see Warnings and Precautions]
 - Priapism [see Warnings and Precautions]
 - Thrombotic thrombocytopenic purpura (TTP) [see Warnings and Precautions]
 - Disruption of body temperature regulation [see Warnings and Precautions]
 - Antiemetic effect [see Warnings and Precautions]
 - Increased sensitivity in patients with Parkinson's disease or those with dementia with Lewy bodies [see Warnings and Precautions]
 - Diseases or conditions that could affect metabolism or hemodynamic responses [see Warnings and Precautions]

The most common adverse reactions in clinical trials in subjects with schizophrenia (reported in 5% or more of subjects treated with INVEGA® and at least twice the placebo rate in any of the dose groups) were extrapyramidal symptoms, tachycardia, and akathisia. The most common adverse reactions in clinical trials in patients with schizoaffective disorder (reported in 5% or more of subjects treated with INVEGA® and at least twice the placebo rate) were extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis.

The most common adverse reactions that were associated with discontinuation from clinical trials in subjects with schizophrenia (causing discontinuation in 2% of INVEGA®-treated subjects) were nervous system disorders. The most common adverse reactions that were associated with discontinuation from clinical trials in subjects with schizoaffective disorder were gastrointestinal disorders, which resulted in discontinuation in 1% of INVEGA®-treated subjects. [See Adverse Reactions]

The safety of INVEGA® was evaluated in 1205 adult subjects with schizophrenia who participated in three placebo-controlled, 6-week, double-blind trials, of whom 850 subjects received INVEGA® at fixed doses ranging from 3 mg to 12 mg once daily. The information presented in this section was derived from pooled data from these three trials. Additional safety information from the placebo-controlled phase of the long-term maintenance study, in which subjects received INVEGA® at daily doses within the range of 3 mg to 15 mg (n=104), is also included.

The safety of INVEGA® was also evaluated in 622 adult subjects with schizoaffective disorder who participated in two placebo-controlled, 6-week, double-blind trials. In one of these trials, 206 subjects were assigned to one of two dose levels of INVEGA®: 6 mg with the option to reduce to 3 mg (n = 108) or 12 mg with the option to reduce to 9 mg (n = 98) once daily. In the other study, 214

subjects received flexible doses of INVEGA® (3-12 mg once daily). Both studies included subjects who received INVEGA® either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of INVEGA® (adverse drug reactions) based on the comprehensive assessment of the available adverse event information. A causal association for INVEGA® often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizophrenia: *Table 1* enumerates the pooled incidences of adverse reactions reported in the three placebo-controlled, 6-week, fixed-dose studies, listing those that occurred in 2% or more of subjects treated with INVEGA® in any of the dose groups, and for which the incidence in INVEGA®-treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo.

Table 1. Adverse Reactions Reported by > 2% of INVEGA®-Treated Subjects with Schizophrenia in Three Short-Term, Fixed-Dose, Placebo-Controlled Clinical Trials *: Body System or Organ Class Dictionary-Derived Term followed by Percent of Patients Reporting Event Placebo (N=355) first, INVEGA® 3 mg once daily (N=127) second, 6 mg once daily (N=235) third, 9 mg once daily (N=246) fourth, 12 mg once daily (N=242) fifth: Total percentage of subjects with adverse reactions: 37, 48, 47, 53, 59; Cardiac disorders: Atrioventricular block first degree 1, 2, 0, 2, 1; Bundle branch block 2, 3, 1, 3, <1; Sinus arrhythmia 0, 2, 1, 1, <1; Tachycardia 7, 14, 12, 12, 14; Gastrointestinal disorders: Abdominal pain upper 1, 1, 3, 2, 2; Dry mouth 1, 2, 3, 1, 3; Salivary hypersecretion<10<114; General disorders: Asthenia 1, 2, <1, 2, 2; Fatigue 1, 2, 1, 2, 2; Nervous system disorders: Akathisia 4, 4, 3, 8, 10; Dizziness 4, 6, 5, 4, 5; Extrapyramidal symptoms 8, 10, 7, 20, 18; Headache 12, 11, 12, 14, 14; Somnolence 7, 6, 9, 10, 11; Vascular disorders: Orthostatic hypotension 1, 2, 1, 2, 4. * Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA® dose groups and which occurred at greater incidence than in the placebo group. Data are pooled from three studies; one study included once-daily INVEGA® doses of 3 mg and 9 mg, the second study included 6 mg, 9 mg, and 12 mg, and the third study included 6 mg and 12 mg [see Clinical Studies [14] in full PI]. Extrapyramidal symptoms includes the terms dyskinesia, dystonia, extrapyramidal disorder, hypertonia, muscle rigidity, oculogyration, parkinsonism, and tremor. Somnolence includes the terms sedation and somnolence. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased. Adverse reactions for which the INVEGA® incidence was equal to or less than placebo are not listed in the table, but included the following: vomiting

Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizoaffective Disorder: Table 2 enumerates the pooled incidences of adverse reactions reported in the two placebo-controlled 6-week studies, listing those that occurred in 2% or more of subjects treated with INVEGA® and for which the incidence in INVEGA®-treated subjects was greater than the incidence in subjects treated with placebo.

Table 2. Adverse Drug Reactions Reported by \geq 2% of INVEGA®-Treated Subjects with Schizoaffective Disorder in Two Double-Blind, Placebo-Controlled Clinical Trials: Body System or Organ Class Dictionary-Derived Term followed by Placebo (N=202) first, INVEGA® 3-6 mg once-daily fixed-dose range (N=108) second, INVEGA® 9-12 mg once-daily fixed-dose range (N=98) third, INVEGA® 3-12 mg once-daily flexible dose (N=214) fourth: Total percentage of subjects with adverse reactions: 32, 48, 50, 43; Cardiac disorders: Tachycardia 2, 3, 1, 2; Gastrointestinal disorders: Abdominal discomfort/Abdominal pain upper 1, 1, 0, 3; Constipation 2, 4, 5, 4; Dyspepsia 2, 5, 6, 6; Nausea 6, 8, 8, 5; Stomach discomfort 1, 0, 1, 2; General disorders: Asthenia 1, 3, 4, <1; Infections and Infestations: Nasopharyngitis 1, 2, 5, 3; Rhinitis 0, 1, 3, 1; Upper respiratory tract infection 1, 2, 2, 2; Investigations: Weight increased 1, 5, 4, 4; Metabolism and nutrition disorders: Decreased appetite Increased 1, 5, 4, 4; Metabolism and nutrition disorders: Decreased appetite <1, 1, 0, 2; Increased appetite <1, 3, 2, 2; Musculoskeletal and connective tissue disorders: Back pain 1, 1, 1, 3; Myalgia <1, 2, 4, 1; Nervous system disorders: Akathisia 4, 4, 6, 6; Dysarthria 0, 1, 4, 2; Extrapyramidal symptoms 8, 20, 17, 12; Somnolence 5, 12, 12, 8; Psychiatric disorders: Sleep disorder <1, 2, 3, 0; Respiratory, thoracic and mediastinal disorders: Cough 1, 1, 3, 1; Pharyngolaryngeal pain <1, 0, 2, 1. * Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA® dose groups and which occurred at oreater incidence than in the placeho group. Data are pooled from two</p> occurred at greater incidence than in the placebo group. Data are pooled from two studies. One study included once-daily INVEGA® doses of 6 mg (with the option to reduce to 3 mg) and 12 mg (with the option to reduce to 9 mg). The second study included flexible once-daily doses of 3 to 12 mg. Among the 420 subjects treated with INVEGA®, 230 (55%) received INVEGA® as monotherapy and 190 (45%) received INVEGA® as an adjunct to mood stabilizers and/or antidepressants. Somnolence includes the terms sedation and somnolence. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased. All EPS-related terms are grouped under "extrapyramidal symptoms".

Monotherapy versus Adjunctive Therapy: The designs of the two placebocontrolled, 6-week, double-blind trials in subjects with schizoaffective disorder included the option for subjects to receive antidepressants (except monoamine oxidase inhibitors) and/or mood stabilizers (lithium, valproate, or lamotrigine). In the subject population evaluated for safety, 230 (55%) subjects received INVEGA® as monotherapy and 190 (45%) subjects received INVEGA® as an adjunct to mood stabilizers and/or antidepressants. When comparing these 2 subpopulations, only nausea occurred at a greater frequency (\geq 3% difference) in subjects receiving INVEGA® as monotherapy.

Other Adverse Reactions Observed During Premarketing Evaluation of INVEGA®:

The following additional adverse reactions occurred in $<\!2\%$ of INVEGA®-treated subjects in the above schizophrenia and schizoaffective disorder clinical trial datasets.

Cardiac disorders: bradycardia, palpitations

Eye disorders: vision blurred

Gastrointestinal disorders: abdominal pain, small intestinal obstruction, swollen tongue

General disorders: edema

Immune system disorders: anaphylactic reaction

Nervous system disorders: dizziness postural, grand mal convulsion, lethargy, syncope

Psychiatric disorders: nightmare

Reproductive system and breast disorders: amenorrhea, breast discharge, breast engorgement, breast pain, erectile dysfunction, galactorrhea, gynecomastia, menstruation irregular

Vascular disorders: hypotension, ischemia

Discontinuations Due to Adverse Reactions: Schizophrenia Trials:The percentages of subjects who discontinued due to adverse reactions in the three schizophrenia placebo-controlled, 6-week, fixed-dose studies were 3% and 1% in INVEGA®- and placebo-treated subjects, respectively. The most common reasons for discontinuation were nervous system disorders (2% and 0% in INVEGA®- and placebo-treated subjects, respectively).

Schizoaffective Disorder Trials: The percentages of subjects who discontinued due to adverse reactions in the two schizoaffective disorder placebo-controlled 6-week studies were 1% and <1% in INVEGA®- and placebo-treated subjects, respectively. The most common reasons for discontinuation were gastrointestinal disorders (1% and 0% in INVEGA®- and placebo-treated subjects, respectively).

Dose-Related Adverse Reactions: Schizophrenia Trials: Based on the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in subjects with schizophrenia, among the adverse reactions that occurred with a greater than 2% incidence in the subjects treated with INVEGA®, the incidences of the following adverse reactions increased with dose: somnolence, orthostatic hypotension, akathisia, dystonia, extrapyramidal disorder, hypertonia, parkinsonism, and salivary hypersecretion. For most of these, the increased incidence was seen primarily at the 12 mg dose, and, in some cases, the 9 mg dose.

Schizoaffective Disorder Trials: In a placebo-controlled, 6-week, high- and low-dose study in subjects with schizoaffective disorder, akathisia, dystonia, dysarthria, myalgia, nasopharyngitis, rhinitis, cough, and pharyngolaryngeal pain occurred more frequently (i.e., a difference of at least 2%) in subjects who received higher doses of INVEGA® compared with subjects who received lower doses.

Demographic Differences: An examination of population subgroups in the three placebo-controlled, 6-week, fixed-dose studies in subjects with schizophrenia and in the two placebo-controlled, 6-week studies in subjects with schizoaffective disorder did not reveal any evidence of clinically relevant differences in safety on the basis of gender or race alone; there was also no difference on the basis of age [see Use in Specific Populations].

Extrapyramidal Symptoms (EPS): Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in subjects with schizophrenia provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline) which broadly evaluates national from baseline) which evaluates akathisia, (3) use of anticholinergic medications to treat emergent EPS (*Table 3*), and (4) incidence of spontaneous reports of EPS (*Table 4*). For the Simpson-Angus Scale, spontaneous EPS reports and use of anticholinergic medications, there was a dose-related increase observed for the 9 mg and 12 mg doses. There was no difference observed between placebo and INVEGA® 3 mg and 6 mg doses for any of these EPS measures.

Table 3. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Ratings Scales and Use of Anticholinergic Medication – Schizophrenia Studies: EPS Group followed by Percentage of Patients Placebo (N=355) first, INVEGA® 3 mg once daily (N=127) second, 6 mg once daily (N=235) third, 9 mg once daily (N=246) fourth, 12 mg once daily (N=242) fifth: Parkinsonism^a 9, 11, 3, 15, 14; Akathisia^b 6, 6, 4, 7, 9; Use of anticholinergic medications^c 10, 10, 9, 22, 22. a: For Parkinsonism, percent of patients with Simpson-Angus global score > 0.3 (Global score defined as total sum of items score divided by the number of items); b: For Akathisia, percent of patients with Barnes Akathisia Rating Scale global score ≥ 2 ; c: Percent of patients who received anticholinergic medications to treat emergent EPS

Table 4. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies: EPS Group followed by Percentage of Patients Placebo (N=355) first, INVEGA® 3 mg once daily (N=127) second, 6 mg once daily (N=235) third, 9 mg once daily (N=246) fourth, 12 mg once daily (N=242) fifth: Overall percentage of patients with EPS-related AE 11, 13, 10, 25, 26; Dyskinesia 3, 5, 3, 8, 9; Dystonia 1, 1, 1, 5, 5; Hyperkinesia 4, 4, 3, 8, 10; Parkinsonism 2, 3, 3, 7, 6; Tremor 3, 3, 3, 4, 3. Dyskinesia group includes: Dyskinesia, extrapyramidal disorder, muscle twitching, tardive dyskinesia

Dystonia group includes: Dystonia, muscle spasms, oculogyration, trismus Hyperkinesia group includes: Akathisia, hyperkinesia

Parkinsonism group includes: Bradykinesia, cogwheel rigidity, drooling, hypertonia, hypokinesia, muscle rigidity, musculoskeletal stiffness, parkinsonism Tremor group includes: Tremor

Compared to data from the studies in schizophrenia, pooled data from the two placebo-controlled 6-week studies in subjects with schizoaffective disorder showed similar types and frequencies of EPS as measured by rating scales, anticholinergic medication use, and spontaneous reports of EPS-related adverse events. For subjects with schizoaffective disorder, there was no dose-related increase in EPS observed for parkinsonism with the Simpson-Angus scale or akathisia with the Barnes Akathisia Rating Scale. There was a dose-related increase observed with spontaneous EPS reports of hyperkinesia and dystonia and in the use of anticholinergic medications.

Table 5 shows the EPS data from the pooled schizoaffective disorder trials.

Table 5. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizoaffective Disorder Studies: EPS Group followed by Percentage of Patients Placebo (N=202) first, INVEGA® 3-6 mg once-daily fixed-dose range (N=108) second, 9-12 mg once-daily fixed-dose range (N=98) third, 3-12 mg once-daily flexible dose (N=214): Overall percentage of patients with EPS-related AE 11, 23, 22, 17; Dyskinesia 1, 3, 1, 1; Dystonia 1, 2, 3, 2; Hyperkinesia 5, 5, 8, 7; Parkinsonism 3, 14, 7, 7; Tremor 3, 12, 11, 5.

Dyskinesia group includes: Dyskinesia, muscle twitching

Dystonia group includes: Dystonia, muscle spasms, oculogyration

Hyperkinesia group includes: Akathisia, hyperkinesia, restlessness

Parkinsonism group includes: Aradikinesia, hyperkinesia, resuessiess Parkinsonism group includes: Bradykinesia, drooling, hypertonia, muscle rigidity, muscle tightness, musculoskeletal stiffness, parkinsonian gait, parkinsonism

Tremor group includes: Tremor

Dystonia: *Class Effect:* Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Laboratory Test Abnormalities: In the pooled data from the three placebocontrolled, 6-week, fixed-dose studies in subjects with schizophrenia and from the two placebo-controlled, 6-week studies in subjects with schizoaffective disorder, between-group comparisons revealed no medically important differences between INVEGA® and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA® and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA® was associated with increases in serum prolactin [see Warnings and Precautions].

Weight Gain: Schizophrenia Trials: In the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in subjects with schizophrenia, the proportions of subjects meeting a weight gain criterion of \geq 7% of body weight were compared, revealing a similar incidence of weight gain for INVEGA® 3 mg and 6 mg (7% and 6%, respectively) compared with placebo (5%), and a higher incidence of weight gain for INVEGA® 9 mg and 12 mg (9% and 9%, respectively). Schizoaffective Disorder Trials: In the pooled data from the two placebo-controlled, 6-week studies in subjects with schizoaffective disorder, a higher percentage of INVEGA®-treated subjects (5%) had an increase in body weight of \geq 7% compared with placebo-treated subjects (1%). In the study that examined high- and low-dose groups, the increase in body weight of \geq 7% was 3% in the low-dose group, 7% in the high-dose group, and 1% in the placebo group.

Other Findings Observed During Clinical Trials: The safety of INVEGA[®] was also evaluated in a long-term trial designed to assess the maintenance of effect with INVEGA[®] in adults with schizophrenia [see Clinical Studies (14) in full PI]. In general, adverse reaction types, frequencies, and severities during the initial 14-week open-label phase of this study were comparable to those observed in the 6-week, placebo-controlled, fixed-dose studies. Adverse reactions reported during the long-term double-blind phase of this study were similar in type and severity to those observed in the initial 14-week open-label phase.

Postmarketing Experience: The following adverse reaction has been identified during postapproval use of INVEGA®; because this reaction was reported voluntarily from a population of uncertain size, it is not possible to reliably estimate its frequency: priapism.

Adverse Reactions Reported With Risperidone: Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with risperidone can be found in the ADVERSE REACTIONS section of the risperidone package insert.

DRUG INTERACTIONS

Potential for INVEGA® to Affect Other Drugs: Given the primary CNS effects of paliperidone [see Adverse Reactions], INVEGA® should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopamine agonists. Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA® is administered with other therapeutic agents that have this potential [see Warnings and Precautions].

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. *In vitro* studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.

Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No *in vivo* data are available and the clinical relevance is unknown.

Pharmacokinetic interaction between lithium and INVEGA® is unlikely.

In a clinical study, subjects on a stable dose of valproate showed comparable valproate average plasma concentrations when 3-15 mg of INVEGA[®] was added to their existing valproate treatment.

Potential for Other Drugs to Affect INVEGA®: Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While *in vitro* studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, *in vivo* studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. *In vitro* studies have shown that paliperidone is a P-gp substrate.

Co-administration of INVEGA® 6 mg once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state C_{max} and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of INVEGA® should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA® should be re-evaluated and decreased if necessary.

Paliperidone is metabolized to a limited extent by CYP2D6 [see Clinical Pharmacology (12.3) in full PI]. In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA® was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.

Co-administration of a single dose of INVEGA® 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the C_{max} and AUC of paliperidone. Dosage reduction for INVEGA® should be considered when INVEGA® is co-administered with valproate after clinical assessment.

Pharmacokinetic interaction between lithium and INVEGA® is unlikely.

USE IN SPECIFIC POPULATIONS

Pregnancy: <u>Pregnancy Category C.</u>: There are no adequate and well controlled studies of INVEGA[®] in pregnant women. INVEGA[®] should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Use of first generation antipsychotic drugs during the last trimester of pregnancy has been associated with extrapyramidal symptoms in the neonate. These symptoms are usually self-limited. It is not known whether paliperidone, when taken near the end of pregnancy, will lead to similar neonatal signs and symptoms. In animal reproduction studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated during the period of organogenesis with up to 8 times the maximum recommended human dose of paliperidone (on a mg/m² basis).

In rat reproduction studies with risperidone, which is extensively converted to paliperidone in rats and humans, there were increases in pup deaths seen at oral doses which are less than the maximum recommended human dose of risperidone on a mg/m² basis (see risperidone package insert).

Nursing Mothers: Paliperidone is 9-hydroxyrisperidone, the active metabolite of risperidone. In animal studies, risperidone and 9-hydroxyrisperidone were excreted in milk. Risperidone and 9-hydroxyrisperidone are also excreted in human breast milk. Caution should be exercised when INVEGA® is administered to a nursing woman. The known benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone.

Pediatric Use: Safety and effectiveness of INVEGA® in patients < 18 years of age have not been established.

Geriatric Use: The safety, tolerability, and efficacy of INVEGA® were evaluated in a 6-week placebo-controlled study of 114 elderly subjects with schizophrenia (65 years of age and older, of whom 21 were 75 years of age and older). In this study, subjects received flexible doses of INVEGA® (3 mg to 12 mg once daily). In addition, a small number of subjects 65 years of age and older were included in the 6-week placebo-controlled studies in which adult schizophrenic subjects received fixed doses of INVEGA® (3 mg to 15 mg once daily) [*see Clinical Studies* (14) in full PI]. There were no subjects \geq 65 years of age in the schizoaffective disorder studies.

Overall, of the total number of subjects in schizophrenia clinical studies of INVEGA® (n = 1796), including those who received INVEGA® or placebo, 125 (7.0%) were 65 years of age and older and 22 (1.2%) were 75 years of age and older. No overall differences in safety or effectiveness were observed between these

subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with moderate to severe renal impairment [see Clinical Pharmacology (12.3) in full PI], who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.5) in full PI].

Renal Impairment: Dosing must be individualized according to the patient's renal function status [see Dosage and Administration (2.5) in full PI].

Hepatic Impairment: No dosage adjustment is required in patients with mild to moderate hepatic impairment. INVEGA® has not been studied in patients with severe hepatic impairment.

DRUG ABUSE AND DEPENDENCE

Controlled Substance: INVEGA® (paliperidone) is not a controlled substance. Abuse: Paliperidone has not been systematically studied in animals or humans for its potential for abuse. It is not possible to predict the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of $\mathsf{INVEGA}^{\circledast}$ misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).

Dependence: Paliperidone has not been systematically studied in animals or humans for its potential for tolerance or physical dependence.

OVERDOSAGE

Human Experience: While experience with paliperidone overdose is limited, among the few cases of overdose reported in pre-marketing trials, the highest estimated ingestion of INVEGA® was 405 mg. Observed signs and symptoms included extrapyramidal symptoms and gait unsteadiness. Other potential signs and symptoms include those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and somnolence, tachycardia and hypotension, and QT prolongation.

Paliperidone is the major active metabolite of risperidone. Overdose experience reported with risperidone can be found in the OVERDOSAGE section of the risperidone package insert.

Management of Overdosage: There is no specific antidote to paliperidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consideration should be given to the extended-release nature of the product when assessing treatment needs and recovery. Multiple drug involvement should also be considered.

In case of acute overdose, establish and maintain an airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.

The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of paliperidone. Similarly the alpha-blocking properties of bretylium might be additive to those of paliperidone, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of paliperidone-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose, propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide, and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.

Manufactured by:

ALZA Corporation, Vacaville, CA 95688 OR Janssen Cilag Manufacturing, LLC, Gurabo, Puerto Rico 00778

Manufactured for:

Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ 08560

OROS is a registered trademark of ALZA Corporation

©Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2007

Revised: July 2009 10105905B

Osler Institute 140th to 143rd **Psychiatry Review Courses** approved for AMA/PRA category 1 credit

for Written Exams

January 18-22, 2010 - Houston May 3-7 – Philadelphia

for Oral Boards

1-day oral didactic day January 18 – Houston May 3 – Philadelphia 3-day mock oral exams January 19-21 – Houston May 4-6, 2010 – Philadelphia

for Child and Adolescent

November 9-12, 2009 – Baltimore

New – Best of Psych Audio Call Today: (800) 356-7537 www.osler.org Y9X

American Psychiatric Association

PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH

ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER

The Practice Guideline course is available on the APA website. http://archive.psych.org/cme/.

Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder

COURSE DESCRIPTION

The course includes the complete guideline, board-type vignette style multiple-choice questions, and discussion of answers with links back into the guideline text. The course is presented in an easy to use format. Progress is tracked as you move through the course.

CME CREDIT

The Acute Stress Disorder and Posttraumatic Stress Disorder course provides up to 5 AMA PRA Category 1 Credits and allows APA members to print a certificate on completion of the course

- Practice Guideline Courses are Free to APA members. Non APA members may complete APA practice guideline courses for a fee of \$60.00 per course.
- APA Practice guideline courses may be a helpful aide in preparation for ABPN certification and recertification examinations as well as part of a practical lifelong learning program. Practice guideline courses are available on the APA website http://archive.psych.org/cme/.
- The APA is accredited by the ACCME to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For further information, pl American Psychiatric Association, Division of Education, educme@psych.org. Visit our website at http://archive.psych.org/cme/.



SPONSORED BY MONTEFIORE MEDICAL CENTER CREDIT DESIGNATED BY ALBERT EINSTEIN COLLEGE OF MEDICINE Accreditation Statement: Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CLINICAL NEUROLOGY FOR PSYCHIATRISTS David Myland Kaufman, MD

This intensive three-day weekend course, offered for the 38th year, is designed for psychiatrists in practice and in residency as an update and board preparation. Focusing on essential topics, the course uses lectures, an extensive syllabus, and the new edition of Clinical Neurology for Psychiatrists, David M. Kaufman (6th edition, Elsevier).

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 25 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHIATRY FOR PSYCHIATRISTS Andrea J. Weiss, MD and David Myland Kaufman, MD

This two-day course will be a pre-test that complements standard psychiatry review courses and completes the review in Clinical Neurology for Psychiatrists. An expert group of faculty who are experienced and well-informed about modern psychiatry and test-taking strategies present essential information through a series of test-type questions utilizing an audience response system and using answers for discussions and explanations.

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 16 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

MAINTENANCE OF CERTIFICATION COURSES

THE PSYCHIATRY RECERT COURSE Dan Smuckler, MD, Andrea J. Weiss, MD and David Myland Kaufman, MD

This intensive two-day course designed for psychiatrists reviews the psychiatric information likely to appear on the recertification examination. It will cover current evidence-based treatments for psychiatric disorders, emphasizing clinical matters and advances in diagnosis and treatment. Presentation of the material will be in a mixed format, with both lecture and question-and-answer utilizing audience response system keypads.

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 14.5 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

THE CHILD AND ADOLESCENT PSYCHIATRY RECERT COURSE Audrey Walker, MD, Andrea J. Weiss, MD and David Myland Kaufman, MD

This intensive one-day course designed for child and adolescent psychiatrists reviews material likely to be on the recertification examination and provides an update on the diagnosis and treatment of children and adolescents with psychiatric disorders. Presentations are given in a mixed format, with both lecture and question-andanswers utilizing an audience response system. Faculty discuss responses to questions and from there review the content.

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

LOS ANGELES

The Westin Hotel at the Los Angeles Airport 5400 West Century Boulevard Los Angeles, CA 90045 Friday, February 12 to Sunday, February 14, 2010 7:45 AM - 5:30 PM

NEW YORK

The Graduate Center City University of New York (CUNY) Friday, March 19 to Sunday, March 21, 2010 8:15 AM - 6:00 PM

LOS ANGELES

The Westin Hotel at the Los Angeles Airport 5400 West Century Boulevard Los Angeles, CA 90045 Monday, February 15 to Tuesday, February 16, 2010 7:45 AM - 5:30 PM

NEW YORK

The Graduate Center City University of New York (CUNY) Monday, March 22 to Tuesday, March 23, 2010 8:15 AM - 6:00 PM

NEW YORK

SUNY College of Optometry Joseph and Roberta Schwarz Theater 33 West 42nd Street (Between 5th and 6th Avenues) New York, NY 10036 Friday, January 8 to Saturday, January 9, 2010 7:45 AM - 6:00 PM

NEW YORK

SUNY College of Optometry Joseph and Roberta Schwarz Theater 33 West 42nd Street (Between 5th and 6th Avenues) New York, NY 10036 Sunday, January 10, 2010 7:45 AM - 6:00 PM




FOR MORE INFORMATION • Web site Course Information or To Register: www.cnfp.org • Write: CCME, 3301 Bainbridge Avenue, Bronx, NY 10467

[•] E-mail: cme@montefiore.org

[•] Call: 718-920-6674 • Fax: 718-798-2336

The MIT Press



Asylum

INSIDE THE CLOSED WORLD OF STATE MENTAL HOSPITALS

Photographs by Christopher Payne with an essay by Oliver Sacks

"Payne is a visual poet as well as an architect by training, and he has spent years finding and photographing these buildings—often the pride of their local communities and a powerful symbol of humane caring for those less fortunate. His photographs are beautiful images in their own right, and they also pay tribute to a sort of public architecture that no longer exists. They focus both on the monumental and the mundane, the grand facades and the peeling paint."—Oliver Sacks, *Asylum*

216 pp., 111 color photographs, 69 multi-tone b&w illus., 61 b&w images, \$39.95 cloth

To order call 800-405-1619 • http://mitpress.mit.edu • Visit our e-books store: http://mitpress-ebooks.mit.edu

American Psychiatric Association

Glen O. Gabbard, M.D. Principles of Psychodynamic Psychotherapy

Three 20-minute video modules and a multiple-choice quiz, covering:

- Therapeutic Interventions
- Transference
- Countertransference

To order, go to *www.appi.org* ISBN 978-0-89042-348-6 Item # 2348

Glen O. Gabbard, M.D., one of the world's foremost teachers and clinicians in psychoanalysis and psychotherapy, presents three lectures illustrated by slides and video vignettes featuring the interaction between psychiatrist and patient. The lectures demonstrate important concepts in psychodynamic psychotherapy. Participants in the program will learn:

- Basic therapeutic interventions used in psychodynamic psychotherapy
- Manifestations of transference in psychodynamic psychotherapy and when to call attention to them in the course of therapy
- Conceptual framework regarding countertransference and when to use countertransference to enhance understanding of the patient

American <u>Psychiatric</u> Publishing, Inc. American Psychiatric Publishing, Inc. Web: www.appi.org Phone: 703-907-7322 or 1-800-368-5777, Mon-Fri, 9 am to 5:30 pm ET Fax: 703-907-1091 Email: appi@psych.org



Accreditation & Designation Statement: The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Non-Physician Health Care Professionals: The APA acknowledges nonphysician participation in this educational activity through a certificate of participation.

SEE ME FOR WHO I CAN BE

LISA, 32*

3

Part-time Caterer Diagnosis: Bipolar Disorder Recent Episode: Mixed

*Not an actual patient.

GEODON is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic symptoms.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with certain other QT-prolonging drugs. **GEODON has been** associated with prolongation of the QT_c interval. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. Patients who are at risk for significant electrolyte disturbances should have baseline measurements performed before initiating GEODON. Patients on diuretics should be monitored.

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Do you see your patients' full potential?

0

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.

Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision.

Please see brief summary of prescribing information on adjacent page. For more information, please visit www.pfizerpro.com/GEODON



BRIEF SUMMARY. See package insert for full prescribing information.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis—Elderly patients with dementia-related psychosis treated with antipsycholic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsycholic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death drug-treated patients as about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or intectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to abypical antipsycholic drugs, reteated with conventional antipsycholic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsycholic drug as opposed to some characteristic(s) of the patients is not clear. Geodon (ziprasidone) is not approved for the treatment of patients with Dementia-Related Psychosis (see WARMINKS)).

INDICATIONS—GEODON Capsules is indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder with or without psychotic features. GEODON" (ziprasidone mesylate) for Injection is indicated for acute agitation in schizophrenic patients.

Schizophrenic patients. CONTRAINDICATIONS — *QT Prolongation*: Because of GEODON's dose-related prolongation of the QT interval and the known history of OT prolongation (including congenital long QT syndrome), with recent acute myocardial infarction, or with uncompensated heart failure (see WARNINGS). Pharmacokinetic/pharmacodynamic studies between GEODON and other drugs that prolong the OT interval have not been performed. An additive effect of GEODON and other drugs that prolong the OT interval cance the excluded. Therefore, GEODON should not be given with dofetilide, sotaiol, quindine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorptomazine, droperidol, pimozide, sparfloxacin, gatifixoacin, moviditoxacin, haldaratrine, melloquine, pettersensitivity to the product. A the product devalte, doaserte, doaserete, doaserte, doaserte, doaserte, doaserte, doaserte, antipsychotic ungest are a an increase in sk of death. Debut (2015) use the provide the rearriest of patients with dementia-related psychosis (see BOXED WARNING). *Of Prolongation and Risks Oxiden Death*: EECDON use should be avoided in combination with other drugs that are known to prolong the OT, interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the OT, interval. Such drugs should not be prescribed with identification of a study directly comparing the OTA; prolonging effect of GEDON with several other drugs that have been consistently observed to prolong the OT, interval. Such drugs should not be prescribed with several other drugs the transmit of the other sections of the several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in OT, from baseline for GEDON ranged from approximately Identification of other drugs that have been consistently observed to protong the 0T, interval. Such drugs should not be prescribed with GECDODN. A tudy directly comparing the 0T/0T, erplonging effect of GEDODN with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in 0T, from baseline for GEODON anged from approximately 9 to 14 mises egreater than for four of the comparator drugs (risperidone, olanzapine, quetlapine, and haloperidol), but was approximately 14 mise cless than the prolongation observed for thins study, the effect of GEODON on Circle at the locumpared to placeb by approximately 10 mises at the highest recommended daily does of 160 mg. In clinical trials the electrocardiograms of 2/2988 (0.06%) GEODON patients and 1/440 (0.23%) placebo patients revealed 07, intervals exceeding the potentially clinically relevant threshold of 500 msec. In the GEODON patients, neither case suggested a role of GEDON. Some drugs that prolong the 0T/0T, interval have been associated with the occurrence of lorsade de pointes and with sudden umexplained deshi. The relationship of CT prolongation to lorsade de pointes is clearest for larger increases (20 msec and greater) but it's possible that smaller 0T/0T, interval have been associated with the occurrence of lorsade edits. Such as those with hypokalemia, hypomagnesemia, or genetic predisposition. Although torsade de pointes has not been observed in association with the use of GEDOON at recommended doss in greanketing studies, experience is too limited to rule out an increase in 0T, from baseline for GEODON (20 mg the 30 mg) or haloperidol (7.5 mg then 10 mg) given tour hours apart. Note that a 30 mg dose of intramuscular GEDOON (20 mg the 30 mg) or haloperidol (7.5 mg then 10 mg) given tour hours apart. Note that a 30 mg dose of intramuscular GEODON (20 mg the 30 mg) or haloperidol (7.5 mg then 10 mg) given tour hours apart. Note that a 30 mg dose of intramuscular GEODON (20 mg the 30 m torm mound or a megabrace bage in the manufacture of the second of the second back of the since recurrences of NMS have been reported. Tardive Dyskinesia (TD): A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Altowidg the prevalence of TD appears to be highest among the delayt, especially elderly wormen, it is impossible to regulate output optime eldic, at the inception of antipsychotic treatment, which patients are likely to develop TD. It signs and symptoms of TD appear in a patient on GEDOD M, roug discontinuation should be considered. Hyperglycemia and Diabets Mellius: Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with alypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEDOD M, and it is not known if GEDOD M is associated with these events. Patients treated with an alypical antipsychotic schuld be monitored for symptoms of hyperglycemia. **PRECAUTIONS** — **General:** Basi, In premarketing triats, about 5% of GEDOD N patients developed rash and/or unicaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was dose related, although the finding might also be explained by longer exposure in higher-dose patients. Several patients with rash had signs and symptoms of associated with dizziness, e.g., elevated WBCs. Most patients improved promptly upon treatment with antihistamines or steroids and/or upon discontinuation of GEDODN, and all patients were reported to recover compteley. Upon appearance of rash two which an alterative eliology cannot be identified. GEDODN hould be discontinued. <u>Orthostatic Hypotension</u>. GEODN may indive and there there discover with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its α_r adrenergic antagonist properties. Syncope was reported in 0.6% of GEODON patients. Gease A with particular cautinn in patients with known cardinovacutari d autor english analysis properties. Sprace was reported in the second of the constraint and the autor in particular laboration apatients with known cardiovascular disease (history of mycerarial infraction or ischemic heard disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). <u>Seizures</u>: In clinical trials, seizures occurred in 0.4% of GEODON patients. There were treament with an universe intervention of the second secon cautiously in patients at risk for aspiration oneumonia. (See also Boxed WARNING, WARNINGS: Increased Mortality in Elderly Patients catology in potentials in this of a spheric in potential as the stab back within the method. Interest in the sectors, GEODON elevates prolactin levels in humans. Tissue culture experiments indicate that approximately one third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class Healthe values and subject in object mode subject on the subject of values and values of values patients in short-term clinical trials. Since GEODON has the potential to impair judgment, thinking, or motor skills, patients should be patients in short-term clinical trials. Since GEODON has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably contain that GEODON therapy does not affect them adversely. <u>Prapism</u>: One case of priapism was reported in the premarketing database. <u>Body Temperature Regulation</u>. Although not reported with GEODON in premarketing trials, suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. GEODON prescriptions should be written for the smallest quantity of capsules consistent with god patient management to reduce over body <u>GeoDoN</u> has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart GeoDoN has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical taulies. Because of the risk of QL prolongation and orthostatic hypotension with GEODON, caution should be observed in cardiac patients (see <u>QT Prolongation and Risk of Sudden Deathin</u> WANNINGS and <u>Orthostatic Hypotension</u> in **PRECAUTIONS**). *Information for Patients*: To ensure safe and effective use of GEODON, the

on and instructions in the Patient Information Sectionshould be discussed with patients. Laboratory Tests: Patients being considered Information and instructions in the Patern information according to the Decision with paterns. Laboratory resist: and the magnetisum for GEDDON treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnetisum measurements. Low serum potassium and magnesium should be repleted before treatment. Patients who are started on diuretics during GEDDON therapy need periodic monitoring of serum potassium and magnesium. Discontinue GEDDON in patients who are started on diuretics during GEDDON therapy need periodic monitoring of serum potassium and magnesium. Discontinue GEDDON in patients who are started on diuretics during genistent 01, measurements-Solo mess (see WARMINGS). *Drug Interactions*; (1) GEDDON should not build be used with any drug that prolongs the 01 interval. (2) Given the primary CNS effects of GEDDON, caution should be used when it is taken in combination with other centrally the QT interval. (2) Given the primary CNS effects of GEODON, caution should be used when it is taken in combination with their centrally acting drugs. (3) Because of its potential for inducing hypotension, GEODON may enhance the effects of certain antihypertensive agents. (4) GEODON may antaponize the effects of levologa and dopamine agonists. <u>Effect of Other Drugs on GEODON</u>: Carbanezpine: 200 mg bid for 21 days, increased the AUC and C_{max} of GEODON by about 35%- 40%. *Cimetidine*, 800 mg of for 2 days, sincreased the AUC and C_{max} of GEODON by about 35%-40%. *Cimetidine*, 800 mg of for 2 days, sincreased the AUC and C_{max} of GEODON by about 35%-40%. *Cimetidine*, 800 mg of for 2 days, sincreased the AUC and C_{max} of GEODON by about 35%-40%. *Cimetidine*, 800 mg of for 2 days, sid not affect GEODON pharmacokinetics, coadministration of 30 mL. of Maakadudi not affect GEODON pharmacokinetics, population pharmacokinetics, and significant pharmacokinetics analysis of schizophrenic patients in controlled clinical trials has not revealed any clinically significant pharmacokinetics advises of schizophrenic patients in controlled of GEODON and <u>Other Drugs</u>. In vitro studies revealed little potential for GEODON to interfere with the metabolism of drugs cleared primarity by CYP120, CYP205, CYP205, and CYP344, and tittle potential for full interactions with beatzprimes at the levol or real clearance of thitium. GEODON 20 mg bid di not affect the pharmacokinetics of concomitantly administered ocar contraceptives, ethinyl estratiol (0.03 mg) and levonorgestrel (0.15 mg). Consistent with in vitro results, a study in normal healthy volunteers showed that GEODON did not alifer the metabolism of *dextromethorphan/dextromethorphan/dextromphan-iss. Mutagenesis*, *Mutagenesis*, *Mutag* state level or renal clearance of lithium. GEODON 20 mg bid did not affect the pharmacokinetics of concomitatly administered oral contraceptive ethniketstatiol (0.03 mg) and levenorestrel (0.15 mg). Consistent with invitro results, astudy in normal healthy volunteers showed that GEODON did not alter the metabolism of *dextomethorphan* (24VPD6 model substrate, to its major metabolite, dextorphan. There was no statistically significant change in the urinary dextomethorphan/dextorphan ratio. *Carcinogenesis, Mutagenesis, Impairment of Ferlity*: Lifetime carcinogenicity studies were conducted with GEODON in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In fernale mice there were dose-related increases in serum prolactin in ree observed in a 1-month dielary study in female, but not male, mice. GEODON had no effect on serum prolactin in ree observed in a 1-month dielary study in female, but not male, mice. GEODON had no effect on serum prolactin in ree unors in rodents is unknown (see <u>hyperprolactinemia). Mutagenesis</u>: There was a reproducible mutagenic response in the Arnes assay in one strain of *S. typhimurium* in the basence of metabolic activation. Positive results were obtained in both the or throm comma alteration assay in human hymphocytes. <u>Immatentof Ferlity</u>; GEODON in creased time to copulation in Sprague-Dawley rati in two ferlity and early embryonic development studies at doses of 100 hs (0.04 (0.5 to 8 times the MHEO 10 200 mg/dg) on a mg/m basis). Fertitig rate was reduced to mg/m basis. The fereting the development studies at doses of 100 hs (0.04 (0.5 to 8 times the MHEO 10 as en adjectang on a mg/m basis). Fertify rate was reduced to the secreted in human milk. It is recommended that women receiving GEODON is would not the sets feed. *Pediatric User*. The state and effectivenes as of feed to near advectang and two in what amount. GEODON not rist metabolites are exceted in human milk. It is recommended that women receivi adverse events that occurred during acute therapy, including only those events that occurred in 2% of GEDOD patients and at a greater incidence than in placebo. Schizophrenia: <u>Body as a Whole</u>—sathenia, accidental injury, chest gain. <u>Cardiovascular</u> – tachycardia. <u>Digestive</u>—nausea, constipation, dyspepsia, diarrhea, drymouth, anorexia, <u>Nervous</u>—extrapyramidal symptoms, somnolence, akathisia, dizziness. <u>Respiratory</u>—respiratory tract infection, thimits, cough increased. <u>Skin and Appendages</u>—rash, funged emrathis. <u>Special</u> <u>Bestive</u>—nausea, diarrhea, drymouth, womiting, increased salvation, tongue edema, dysphagia, <u>Musculoskeletal</u>—mayagia, <u>Nervous</u>— somnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypesthesia, speech disorder. <u>Repiratory</u>—pharyngits, dyspina. <u>Skin and Appendages</u>—fungal dermathis. <u>Special</u> <u>Bestive</u> sevent to dose for the following: asthenia, postural hypotension, norexia, dry schizophrenia trials revealed an apparent relation of adverse event to dose for the following: asthenia, postural hypotension, anorexia, dry much increased eliationa of their dationa asthenet drivese event to dose for the following: asthenia, postural hypotension, anorexia, dry schizophrenia trials revealed an apparent relation of adverse event to dose for the following: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthratiga, anviety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. Extrapyranidal Symptoms (EPS): The incidence of reported EPS for GEDON patients in the short-term, placebo-controlled schizophrenia trials was 14% vs 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale and the Barnes Akathisia Scale did not generally show a difference between GEODON and placebo. **Dystonia**: Prolonged abnormal contractions of muscle groups may occur in susceptible individual during first lew days of treatment. Dystonia may occur at any dose level but with greater frequency and sevenity with high potency and at higher doses of first generation antipsychotic drugs. Elevated risk is observed in melas and younger age groups. **Vital Sign Changes:** GEODON size sosciated with orthostatic hypotension (see PRECAUTIONS). **Weight Gain:** In short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of 2-7% of body weight were compared, revealing a statistically significantly greater incidence of weight gain for GEODON patients (10%) vs placebo patients (4%). A median weight gain for GEODON adjents vs event in d.4%, of both GEODON and schizophrenia trais, me proportions of patients meeting a weight gain criterion of 2r% of body weight were compared, revealing a statistically significantly grater incidence of weight gain for GEDDON patients (10%) vs placebo patients (4%). A median weight gain of 0.5 kg was observed in GEDON patients vs 0.0 kg in placebo patients. Weight gain was reported as an adverse event in 0.4% of both GEDDON and placebo patients. During long-term therapy with GEDON, patients. Weight gain was reported as an adverse event in 0.4% of both GEDON and placebo patients. During long-term therapy with GEDON, a categorization of patients at baseline on the basis of body mass index (BMI) showed the greatest mean weight gain and the highest incidence of clinically significant weight gain (1 - 4%) of body weight) in patients with a "low BMI (-22) compared to normal (23-27) or overweight (-27) patients. There was a maxe meight gain (1 - 4%) of body weight) in patients with a "low" baseline BMI, 0.0 kg for patients with a "low" BMI, and a 13 kg mean weight loss for patients with a "light" BMI. *CEG G Changes:* GEDDON is associated with an increase in the OT, interval (see WARNINGS). In schizophrenia trials, GEDOON was associated with a mean increase in heart tae (1 1 4 beats per minute compared to a 20 beats per minute done associated were events are those occurring in tal tess 1/100 patients. *Chizophrenia:* <u>Body as a Whole</u>— *Frequent* abdominal pain, flu syndrome, fever, accidental fail, face edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident. <u>Cardiovascular System</u>— *Frequent* tachycardie, hypotherisin, public system)—*Frequent* anoraxie, vorting inference, attal full disease increases of the patients, or weight as increases of hypotension, Inferuent anoraxy, curvedia, angina pectoria, statial full triange, dysphagi, torque edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident. <u>Cardiovascular System</u>—*Frequent* tachycardis, hypotheretina, thy inperimenta, inpocinosistenia, inperiatenia, inpocatenia, hypocalenia, hypolycenia, inpolatenia, inpopulationia, guodos duralacios decresased, gout, hyperchlorenia, hypocatenia, hypocalenia, hypoglycenia reaction, hypomanesemia, letosis, respiratovalialiosis. <u>Musculoskeletal System</u> — Frequent: myalgia: *Infrequent*: tenosynovitis: *Rare*: myopathy. <u>Nervous System</u> — Frequent: agitation extrapyramidal syndrome, tremor, dystonia, hypertonia, dyskinesia, hostility, twitching, paresthesia, confusion, veritop, hypokinesia, hyperkinesia, abnormal gait, coulogyric crisis, hypertensia, advas, a mesia, cognetic el foldity, delirum, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy: *Infrequent*: paralysis; Arar myoclonus, nystagmus, torticollis, circumoral paresthesia, opishtotonos, reflexes increased, interopant, moraldan bargatori, ba tom make immediate a supprotecting by groups, the made section of the provide status of protecting of the section of the secti GEDDON: In these studies, the most commonly observed adverse events associated with the use of intramuscular GEDDON (25%) and observed at a rate on intramuscular GEDDON (in the higher dose groups) at least twice that of the lowest intramuscular GEDDON group were headache (13%), nausea (12%), and somnolence (20%). Adverse Events at an incidence > 1% in Short Term Fixed-Dose intramuscular Trats: The following list enumerates the treatment-emergent adverse events that occurred in > 1% of GEDDON groups) and at least twice that of the lowest intramuscular GEDDON (species events that occurred in > 1% of GEDDON groups) and at least twice that of the lowest intramuscular GEDDON group. <u>Body as a Whole</u> — headache, injection site pain, asthenia, addominal pain, flu syndrome, back pain. <u>Cardiovascular</u> — postural hypotension, hypertension, bradycardia, vasoditation. <u>Digestive</u> — nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. <u>Nervoue</u> — diziness, anviety, insomnia, somnolence, akathisa, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. <u>Respiratory</u> — thintis. <u>Skin and Agenedages</u> — fururculosis, swarding <u>Urogential</u> — dysmenorthea, priapism. **DRUG ABUSE AND DEPENDENCE**—Controlled Substance Class: GEDODN is not a controlled substance. <u>OVENDOSAGE</u> — **DRUG ABUSE AND DEPENDENCE**—Controlled Substance (Jass: GEDODN) is not a controlled substance. <u>OVENDOSAGE</u> — **DRUG ABUSE AND DEPENDENCE**—Controlled Substance (Janse): **DRUG ABUSE AND DEPENDENCE**—Controlled Substance (Janse): **DRUG ABUSE** AND **DEPENDENCE**—Controlled Substance (Janse): **DRUG ABUSE** AND **DEPENDENCE**—Contro premarketing trials in over 5400 patients, accidental or intentional overdosage of GEODON was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (BP 200/95).



Complex puzzles. Comprehensive solutions.

At Western Psychiatric Institute and Clinic of UPMC, we take on complex disorders that some other centers won't even attempt to treat.

But whether a patient has a difficult-to-treat disorder or one more easily treated, teams of specialists in psychiatry, psychopharmacology, clinical psychology, and medicine craft complete, individualized treatment plans that draw upon the latest clinical research, much of it conducted by our own investigators. Whether we're interpreting our clinical trial data or a patient's lab results, our work to advance the understanding and treatment of bipolar disorder,

eating disorders, autism, and geriatric behavioral health issues is world-class. In fact, we have one of the world's most comprehensive programs for mood disorders, with research-based treatments for patients at every level of need, at every stage of life.

With more than 400 inpatient psychiatric beds and 75 ambulatory programs, we care for people when they're feeling their worst and support them when they're at their best, back with their families in their home towns. Each year, Western Psychiatric helps some 30,000 people of all ages — at all stages of recovery, from all over the world — live healthier and more productive lives.



Affiliated with the **University of Pittsburgh School of Medicine**, UPMC is ranked among the nation's best hospitals by *U.S.News & World Report*.

RELAPSE.

 Patients treated with atypical oral antipsychotics may be missing their medication for about one-third of the year (110 days)¹

RELAPSE.

Despite patients continuing to miss their medication, long-acting medications are being used later in treatment²

*While no medication can guarantee a patient will be relapse-free, using long-acting, professionally administered medication can help you recognize a missed dose and intervene.

IMPORTANT SAFETY INFORMATION

INVEGA® SUSTENNA[™] (paliperidone palmitate) extended-release injectable suspension is indicated for the acute and maintenance treatment of schizophrenia in adults.

IMPORTANT SAFETY INFORMATION FOR INVEGA® SUSTENNA[™]

WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® SUSTENNA" (paliperidone palmitate) is not approved for the treatment of patients with dementia-related psychosis.

- Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone, which is a metabolite of risperidone. Therefore paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in INVEGA® SUSTENNA[™].
- Cerebrovascular Adverse Events (CAEs): CAEs, including fatalities and stroke, have been reported in elderly patients with dementia-related psychosis taking oral risperidone in clinical trials. The incidence of CAEs with risperidone was significantly higher than with placebo. INVEGA® SUSTENNA[™] is not approved for the treatment of patients with dementia-related psychosis.
- Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including paliperidone. Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and close medical monitoring, and treatment of any concomitant serious medical problems.
- QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. Avoid the use of drugs that also increase QT interval and in patients with risk factors for prolonged QT interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias. Certain

circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval. • Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose, but can develop after relatively brief treatment at low doses. Elderly women patients appeared to be at increased risk for TD, although it is impossible to predict which patients will develop the syndrome. Prescribing should be consistent with the need to minimize the risk of TD. Discontinue drug if clinically appropriate. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

- Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including INVEGA® SUSTENNA[™]. Patients starting treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Some patients require continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
- Weight Gain: Weight gain has been observed with INVEGA[®] SUSTENNA[™] and other atypical antipsychotic medications. Monitor weight gain.
- Hyperprolactinemia: As with other drugs that antagonize dopamine D₂ receptors, INVEGA® SUSTENNA[™] elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to risperidone, which is associated with higher levels of prolactin elevation than other antipsychotic agents.
- Orthostatic Hypotension and Syncope: INVEGA® SUSTENNA[™] may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period. Monitoring should be considered in patients for whom this may be of concern. INVEGA® SUSTENNA[™] should be used with caution in patients with known cardiovascular disease, cerebrovascular disease or conditions that would predispose patients to hypotension.
- Leukopenia, Neutropenia and Agranulocytosis have been reported with antipsychotics, including paliperidone. Patients with a history of clinically significant low white blood cell count (WBC) or drug-induced leukopenia/neutropenia should have frequent complete blood cell counts during the first few months of therapy. At the first sign of a clinically significant decline in WBC and in the absence of other causative factors, discontinuation of INVEGA® SUSTENNA[™] should be considered. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm[®]) should discontinue INVEGA[®] SUSTENNA[™] and have their WBC followed until recovery.

NOW APPROVED

FOR ACUTE AND MAINTENANCE TREATMENT OF SCHIZOPHRENIA RETHINK THE WAY YOU TREAT



ACT EARLIER WITH NEW ONCE-MONTHLY INVEGA® SUSTENNA[™]

- Once-monthly dosing³
- Demonstrated safety and tolerability profile^{†‡3}
- Significantly delayed time to relapse in the longer-term maintenance study³

[†]Reported in 4 fixed-dose, double-blind, placebocontrolled studies (N=1803). [‡]Reported in the longer-term maintenance study (N=849).

- Potential for Cognitive and Motor Impairment: Somnolence, sedation, and dizziness
 were reported as adverse reactions in subjects treated with INVEGA® SUSTENNA[™].
 INVEGA® SUSTENNA[™] has the potential to impair judgment, thinking, or motor skills.
 Patients should be cautioned about operating hazardous machinery, including motor
 vehicles, until they are reasonably certain that INVEGA® SUSTENNA[™] does not affect them
 adversely, and should use caution when operating machinery.
- Seizures: INVEGA® SUSTENNA[™] should be used cautiously in patients with a history of seizures or with conditions that potentially lower seizure threshold.
- Suicide: The possibility of suicide attempt is inherent in schizophrenia. Close supervision of high-risk patients should accompany drug therapy.
- Administration: For intramuscular injection only. Care should be taken to avoid inadvertent injection into a blood vessel.
- Commonly Observed Adverse Reactions for INVEGA® SUSTENNA[™]: The most common adverse reactions in clinical trials in patients with schizophrenia (≥5% and twice placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal disorder.

References: 1. Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. *Clin Drug Invest.* 2004;24:275-286. 2. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. *J Clin Psychiatry.* 2004;65:120-131. 3. INVEGA® SUSTENNA[™] [Prescribing Information]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc. July 2009.

Please see accompanying brief summary of full Prescribing Information for INVEGA[®] SUSTENNA[™].

Visit www.invegasustenna.com for more information.



© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009 August 2009 01PM09034

Brief Summary

BEFORE PRESCRIBING INVEGA® SUSTENNA™, PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® SUSTENNATM (paliperidone palmitate) is not approved for the treatment of patients with dementia-related psychosis. *[See Warnings and Precautions]*

INVEGA® SUSTENNA™ (paliperidone palmitate) is indicated for the acute and maintenance treatment of schizophrenia in adults [see Clinical Studies (14) in full PI].

CONTRAINDICATIONS

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. Paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the INVEGA® SUSTENNA™ formulation.

WARNINGS AND PRECAUTIONS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. INVEGA® SUSTENNA™ (paliperidone palmitate) is not approved for the treatment of dementia-related psychosis [see Boxed Warning].

Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients With Dementia-Related Psychosis: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. Oral paliperidone and INVEGA[®] SUSTENNATM were not marketed at the time these studies were performed and are not approved for the treatment of patients with dementia-related psychosis *[see also Boxed Warning and Warnings and Precautions]*.

Neuroleptic Malignant Syndrome: A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

The effects of oral paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.

INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate release (C_{max ss} = 113 ng/mL) was more than 2-fold the exposure observed with the maximum recommended 234 mg dose of INVEGA® SUSTENNATM administered in the deltoid muscle (predicted median C_{max ss} = 50 ng/mL). In this same study, a 4 mg dose of the immediate-release oral formulation of paliperidone, for which C_{max ss} = 35 ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% CI: 3.6; 10.1) on day 2 at 1.5 hours post-dose.

In the three fixed-dose efficacy studies of oral paliperidone extended release, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the oral paliperidone 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec).

In the four fixed-dose efficacy studies of INVEGA® SUSTENNA™, no subject experienced a change in QTcLD exceeding 60 msec and no subject had a QTcLD value of > 500 msec at any time point. In the maintenance study, no subject had a QTcLD change > 60 msec, and one subject had a QTcLD value of 507 msec (Bazett's QT corrected interval [QTcB] value of 483 msec); this latter subject also had a heart rate of 45 beats per minute.

Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome and evelop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, INVEGA® SUSTENNA[™] should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reasessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA® SUSTENNA™, drug discontinuation should be considered. However, some patients may require treatment with INVEGA® SUSTENNA™ despite the presence of the syndrome. Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA® SUSTENNA™. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Weight Gain: Weight gain has been observed with INVEGA® SUSTENNA[™] and other atypical antipsychotics. In the 13-week study involving 234 mg initiation dosing, the proportion of subjects with an abnormal weight increase ≥ 7% showed a dose-related trend, with a 5% incidence rate in the placebo group compared with rates of 6%, 8%, and 13% in the INVEGA® SUSTENNA[™] 39 mg, 156 mg, and 234 mg groups, respectively. In the two 13-week, fixed-dose, double-blind, placebo-controlled trials (pooled data), the proportions of subjects meeting a weight gain criterion of ≥ 7% of body weight were 6%, 9%, and 10% in the INVEGA® SUSTENNA[™] 39 mg, 78 mg, and 156 mg groups, respectively, compared with 2% in the placebo group. In the 9-week, fixed-dose, double-blind, placebo-controlled trial, 8% and 6% in the INVEGA® SUSTENNA[™] 39 mg, 78 mg, and 156 mg groups, respectively, compared with 2% in the placebo group. In the 9-week, fixed-dose, double-blind, placebo-controlled trial, 8% and 6% in the INVEGA® SUSTENNA[™] 78 mg and 156 mg groups, respectively, met this criterion compared with 4% in the placebo group.

During the 33-week open-label period (9-week flexible-dose transition phase followed by a 24-week maintenance phase flexible-dose and minimum 12-week fixed dose) of the maintenance trial, 12% of INVEGA® SUSTENNA[™]-treated subjects met this criterion; the mean (SD) weight change from open-label baseline was +0.7 (4.79) kg. In the variable length double-blind phase, this criterion (weight gain of ≥ 7% from double-blind phase to endpoint) was met by 6% of INVEGA® SUSTENNA[™]-treated subjects compared with 3% of placebo-treated subjects; the mean weight change from double-blind baseline was +0.5 kg for INVEGA® SUSTENNA™ compared with -1.0 kg for placebo. Similar results were observed in the open-label extension phase of this study.

Hyperprolactinemia: Like other drugs that antagonize dopamine D₂ receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats [see Nonclinical Toxicology (13.1) in full PIJ. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Orthostatic Hypotension and Syncope: Paliperidone can induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. Syncope was reported in < 1% (4/1293) of subjects treated with INVEGA® SUSTENNA™ in the recommended dose range of 39 mg to 234 mg in the four fixed-dose, double-blind, placebo-controlled trials compared with 0% (0/510) of subjects treated with placebo. In the four fixed-dose efficacy studies, orthostatic hypotension was reported as an adverse event by < 1% (2/1293) of INVEGA® SUSTENNATM-treated subjects compared to 0% (0/510) with placebo. Incidences of orthostatic hypotension and syncope in the long-term studies were similar to those observed in the short-term studies.

INVEGA® SUSTENNA™ should be used with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.

Leukopenia, Neutropenia, and Agranulocytosis: Class Effect: In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including INVEGA®, an oral form of paliperidone. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of INVEGA® SUSTENNA™ should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm³) should discontinue INVEGA® SUSTENNA™ and have their WBC followed until recovery.

Potential for Cognitive and Motor Impairment: Somnolence, sedation, and dizziness were reported as adverse reactions in subjects treated with INVEGA® SUSTENNATM [see Adverse Reactions]. Antipsychotics, including INVEGA® SUSTENNATM, have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that paliperidone therapy does not adversely affect them.

Seizures: In the four fixed-dose double-blind placebo-controlled studies, <1% (1/1293) of subjects treated with INVEGA® SUSTENNA™ in the recommended dose range of 39 mg to 234 mg experienced an adverse event of convulsion compared with <1% (1/510) of placebo-treated subjects who experienced an adverse event of grand mal convulsion.

Like other antipsychotic drugs, INVEGA® SUSTENNA™ should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. INVEGA® SUSTENNA™ and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Suicide: The possibility of suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy.

Priapism: Drugs with alpha-adrenergic blocking effects have been reported to induce priapism. Although no cases of priapism have been reported in clinical trials with INVEGA® SUSTENNA™, priapism has been reported with oral paliperidone during postmarketing surveillance. Severe priapism may require surgical intervention.

Thrombotic Thrombocytopenic Purpura (TTP): No cases of TTP were observed during clinical studies with oral paliperidone or INVEGA® SUSTENNATM. Although cases of TTP have been reported in association with risperidone administration, the relationship to risperidone therapy is unknown.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing INVEGA® SUSTENNA™ to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Administration: INVEGA® SUSTENNA™ is intended for intramuscular injection, and care must be taken to avoid inadvertent injection into a blood vessel [see Dosage and Administration (2.3) in full PIJ.

Antiemetic Effect: An antiemetic effect was observed in preclinical studies with paliperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye's syndrome, and brain tumor.

Use in Patients with Concomitant Illness: Clinical experience with INVEGA® SUSTENNA™ in patients with certain concomitant illnesses is limited [see Clinical Pharmacology (12.3) in full PI].

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

INVEGA® SUSTENNATM has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical trials. Because of the risk of orthostatic hypotension with INVEGA® SUSTENNA™, caution should be observed in patients with known cardiovascular disease [see Warnings and Precautions].

Monitoring: Laboratory Tests: No specific laboratory tests are recommended.

ADVERSE REACTIONS

The following are discussed in more detail in other sections of the labeling:

- Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions]
- Cerebrovascular adverse events, including stroke, in elderly patients with dementiarelated psychosis [see Warnings and Precautions]
- Neuroleptic malignant syndrome [see Warnings and Precautions]
- QT prolongation [see Warnings and Precautions]
- Tardive dyskinesia [see Warnings and Precautions] Tardive dyskinesia [see Warnings and Precautions] Hyperglycemia and diabetes mellitus [see Warnings and Precautions]
- Weight gain *[see Warnings and Precautions]* Hyperprolactinemia *[see Warnings and Precautions]*
- Orthostatic hypotension and syncope [see Warnings and Precautions]
- Leukopenia, neutropenia, and agranulocytosis [see Warnings and Precautions]
- Potential for cognitive and motor impairment [see Warnings and Precautions]
- Seizures [see Warnings and Precautions]
- Dysphagia [see Warnings and Precautions]
- Suicide [see Warnings and Precautions]
- Priapism [see Warnings and Precautions]
- Thrombotic Thrombocytopenic Purpura [see Warnings and Precautions]
- Disruption of body temperature regulation [see Warnings and Precautions]
- Avoidance of inadvertent injection into a blood vessel [see Warnings and Precautions]
- Antiemetic effect [see Warnings and Precautions]
- Increased sensitivity in patients with Parkinson's disease or those with dementia with Lewy bodies [see Warnings and Precautions]
- Diseases or conditions that could affect metabolism or hemodynamic responses [see Warnings and Precautions

Throughout this section, a distinction is made between adverse events and adverse reactions. Adverse events are events reported by the clinician investigator and there is no attempt to assign causality to the study drug. Adverse reactions are adverse events (adverse drug reactions) based on a predetermined method of assessment, e.g., a comparison of adverse event rates for drug and placebo groups for the event of interest. It is not possible to reliably establish causality by considering individual adverse event reports for drug-treated patients. Thus, the section overall is labeled Adverse Reactions, however, individual subsections are labeled adverse reactions or adverse events, depending on what is included in the subsection.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The most common (at least 5% in any INVEGA® SUSTENNA™ group) and likely drug-related (adverse events for which the drug rate is at least twice the placebo rate)

adverse reactions from the double-blind, placebo-controlled trials were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder.

The data described in this section are derived from a clinical trial database (Phase 2 and 3) consisting of a total of 2770 subjects with schizophrenia who received at least one dose of INVEGA® SUSTENNA™ in the recommended dose range of 39 mg to 234 mg and a total of 510 subjects with schizophrenia who received placebo. Among the 2770 INVEGA® SUSTENNA™-treated subjects, 1293 received INVEGA® SUSTENNA™ in four fixed-dose, double-blind, placebo-controlled trials (one 9-week and three 13-week studies). 849 received INVEGA® SUSTENNA™ in the maintenance trial (of whom 205 continued to receive INVEGA® SUSTENNA™ in the maniferance that (0) within 2005 to controlled phase of this study), and 628 received INVEGA® SUSTENNA™ in two non-placebo controlled trials (a noninferiority active-comparator trial and an injection site [deltoid-gluteal] cross-over trial). One of the 13-week studies included a 234 mg INVEGA® SUSTENNA™ initiation dose followed by treatment with either 39 mg, 156 mg, or 234 mg every 4 weeks.

Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide

INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

The majority of all adverse reactions were mild to moderate in severity.

Commonly-Observed Adverse Events in Double-Blind, Placebo-Controlled Clinical Trials: *Table 1* lists the adverse events reported in 2% or more of INVEGA® SUSTENNATM-treated subjects with schizophrenia in the four fixed-dose, double-blind, placebocontrolled trials.

Table 1. Incidence of Treatment Emergent Adverse Events in $\ge 2\%$ of INVEGA® SUSTENNATM-Treated Subjects with Schizophrenia in Four Fixed-Dose, Double-Blind, Placebo-Controlled Trials: System Organ Class Adverse Event followed by Placebo^a (N=510) first, 39 mg (N=130) second, 78 mg (N=302) third, 156 mg (N=312) fourth, 234/39 mg^b (N=160) fifth, 234/156 mg^b (N=165) sixth, 234/234 mg^b (N=163) seventh: Total percentage of subjects with adverse event: 70, 75, 68, 69, 63, 60, 63; Gastrointestinal disorders: Abdominal discomfort/Abdominal pain upper 1, 0, 3, 3, 1, 2, 3; Constipation 5, 3, 5, 5, 2, 4, 1; Diarrhea 2, 0, 3, 2, 1, 2, 2; Dry mouth 1, 3, 1, 0, 1, 1, 1; Nausea 3, 4, 4, 3, 2, 2, 2; Toothache 1, 1, 1, 3, 1, 2, 3; Vomiting 4, 5, 4, 2, 3, 2, 2; General disorders and administration site conditions: Asthenia 0, 2, 1, <1, 0, 1, 1; Fatigue 1, 1, 2, 2, 1, 2, 1; Injection site reactions 2, 0, 4, 6, 9, 7, 10; Infections and infestations: Nasopharyngitis 2, 0, 2, 2, 4, 2, 2; Upper respiratory tract infection 2, 2, 2, 1, 2, 4; Urinary tract infection 1, 0, 1, <1, 1, 1, 2; Injury, poisoning and procedural complications: Skin laceration <1, 2, <1, 0, 1, 0, 0; Investigations: Alanine aminotransferaseincreased 2, 0, 2, 1, 1, 1, 1; Weight increased 1, 4, 4, 1, 1, 1, 2; Musculoskeletal andconnective tissue disorders: Back pain 2, 2, 1, 3, 1, 1, 1, 1, 1, 0, 0; Determine the state of t Musculoskeletal stiffness 1, 1, <1, <1, 1, 1, 2; Myalgia 1, 2, 1, <1, 1, 0, 2; Pain in extremity 1, 0, 2, 2, 2, 3, 0; **Nervous system disorders:** Akathisia 3, 2, 2, 3, 1, 5, 6; Dizziness 1, 6, 2, 4, 1, 4, 2; Extrapyramidal disorder 1, 5, 2, 3, 1, 0, 0; Headache 12, 11, 11, 15, 11, 7, 6; Somnolence/sedation 3, 5, 7, 4, 1, 5, 5; **Psychiatric disorders:** Agitation 7, 10, 5, 9, 8, 5, 4; Anxiety 7, 8, 5, 3, 5, 6, 6; Insomnia 15, 15, 15, 13, 12, 10, 13; Nightmare <1, 2, 0, 0, 0, 0, 0; Suicidal ideation 2, 0, 1, 2, 2, 2, 1; Respiratory, thoracic and mediastinal disorders: Cough 1, 2, 3, 1, 0, 1, 1; Vascular disorders: Hypertension 1, 2, 1, 1, 1, 1, 0. Percentages are rounded to whole numbers. Table includes adverse events that were reported in 2% or more of subjects in any of the INVEGA® SUSTENNA™ dose groups and which occurred at greater incidence than in the placebo group. a Placebo group is pooled from all studies and included either deltoid or gluteal injection depending on study design. ^b Initial deltoid injection of 234 mg followed by either 39 mg, 156 mg, or 234 mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39 mg, 78 mg, and 156 mg) are from studies involving only gluteal injection. [See Clinical Studies (14) in full PI]

Adverse events for which the paliperidone palmitate incidence was equal to or less than placebo are not listed in the table, but included the following: dyspepsia, psychotic disorder, schizophrenia, and tremor. The following terms were combined: somnolence/sedation, breast tenderness/breast pain, abdominal discomfort/abdominal pain upper, and tachycardia/sinus tachycardia/heart rate increased. All injection site reaction-related adverse events were collapsed and are grouped under "Injection site reactions".

Adverse Reactions Observed During the Premarketing Evaluation of INVEGA® SUSTENNA™ Not Listed in Table 1: The following additional adverse reactions occurred in INVEGA® SUSTENNA™-treated subjects in the above four fixed-dose, double-blind, placebo-controlled trials, in the double-blind phase of the maintenance trial, or in INVEGA® SUSTENNA™-treated subjects with schizophrenia who participated in other Phase 3 trials, and were not reported in Table 1. They were determined to be adverse reactions based upon reasons to suspect causility such as timing of onset or termination with respect to drug use, plausibility in light of the drug's known pharmacology, occurrence at a frequency above that expected in the treated population or occurrence of an event typical of drug-induced adverse reactions.

Cardiac disorders: bradycardia, bundle branch block, postural orthostatic tachycardia syndrome, tachycardia

Ear and labyrinth disorders: vertigo

Endocrine disorders: hyperprolactinemia

Eye disorders: oculogyric crisis, eye rolling, vision blurred

Gastrointestinal disorders: salivary hypersecretion, stomach discomfort

Investigations: blood cholesterol increased, blood glucose increased

Metabolism and nutrition disorders: decreased appetite, increased appetite

Nervous system disorders: convulsion, dizziness postural, drooling, dysarthria, dyskinesia, dystonia, hypertonia, lethargy, neuroleptic malignant syndrome, oromandibular dystonia, parkinsonism, psychomotor hyperactivity, syncope

Psychiatric disorders: restlessness

Reproductive system and breast disorders: amenorrhea, erectile dysfunction, galactorrhea, gynecomastia, menstruation irregular, sexual dysfunction

Skin and subcutaneous tissue disorders: pruritus generalized, rash

Vascular disorders: orthostatic hypotension

Discontinuations Due to Adverse Events: The percentages of subjects who discontinued due to adverse events in the four fixed-dose, double-blind, placebo-controlled trials were 5.0% and 7.8% in INVEGA® SUSTENNATM- and placebo-treated subjects, respectively.

Dose-Related Adverse Reactions: Based on the pooled data from the four fixed-dose, double-blind, placebo-controlled trials, among the adverse reactions that occurred at $\geq 2\%$ incidence in the subjects treated with INVEGA® SUSTENNATM, only akathisia increased with dose. Hyperprolactinemia also exhibited a dose relationship, but did not occur at $\geq 2\%$ incidence in INVEGA® SUSTENNATM-treated subjects from the four fixed-dose studies.

Demographic Differences: An examination of population subgroups in the double-blind placebo-controlled trials did not reveal any evidence of differences in safety on the basis of age, gender, or race alone; however, there were few subjects ≥ 65 years of age.

Extrapyramidal Symptoms (EPS): Pooled data from the two double-blind, placebocontrolled, 13-week, fixed-dose trials provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline or score at the end of trial) which broadly evaluates

INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline or score at the end of trial) which evaluates akathisia, (3) use of anticholinergic medications to treat emergent EPS, (4) the Abnormal Involuntary Movement Scale scores (mean change from baseline or scores at the end of trial) (*Table 2*), and (5) incidence of spontaneous reports of EPS (*Table 3*).

Table 2. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Rating Scales and Use of Anticholinergic Medication: Scale followed by Percentage of Subjects Placebo (N=262) first, INVEGA® SUSTENNATM 39 mg (N=130) second, 78 mg (N=223) third, 156 mg (N=228) fourth: Parkinsonism^a 9, 12, 10, 6; Akathisia^b 5, 5, 6, 5; Dyskinesia^c 3, 4, 6, 4; Use of Anticholinergic Medications^d 12, 10, 12, 11. ^aFor Parkinsonism, percent of subjects with Simpson-Angus Total score > 0.3 at endpoint (Total score defined as total sum of items score divided by the number of items) ^bFor Akathisia, percent of subjects with Barnes Akathisia Rating Scale global score ≥ 2 at endpoint °For Dyskinesia, percent of subjects with a score ≥ 3 on any of the first 7 items of the Abnormal Involuntary Movement Scale at endpoint ^dPercent of subjects who received anticholinergic medications to treat emergent EPS

Table 3. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term: EPS Group followed by Percentage of Subjects Placebo (N=262) first, INVEGA® SUSTENNA™ 39 mg (N=130) second, 78 mg (N=223) third, 156 mg (N=228) fourth: Overall percentage of subjects with EPS-related adverse events 10, 12, 11, 11; Parkinsonism 5, 6, 6, 4; Hyperkinesia 2, 2, 2, 4; Tremor 3, 2, 2, 3; Dyskinesia 1, 2, 3, 1; Dystonia 0, 1, 1, 2.

Parkinsonism group includes: Extrapyramidal disorder, hypertonia, musculoskeletal stiffness, parkinsonism, drooling, masked facies, muscle tightness, hypokinesia

Hyperkinesia group includes: Akathisia, restless legs syndrome, restlessness

Dyskinesia group includes: Dyskinesia, choreoathetosis, muscle twitching, myoclonus, tardive dyskinesia

Dystonia group includes: Dystonia, muscle spasms

The results across all phases of the maintenance trial exhibited comparable findings. In the 9-week, fixed-dose, double-blind, placebo-controlled trial, the proportions of Parkinsonism and akathisia assessed by incidence of rating scales were higher in the INVEGA® SUSTENNATM 156 mg group (18% and 11%, respectively) than in the INVEGA® SUSTENNATM 78 mg group (9% and 5%, respectively) and placebo group (7% and 4%, respectively).

In the 13-week study involving 234 mg initiation dosing, the incidence of any treatment-emergent EPS-related adverse events was similar to that of the placebo group (8%), but exhibited a dose-related pattern with 6%, 10%, and 11% in the INVEGA® SUSTENNATM 234/39 mg, 234/156 mg, and 234/234 mg groups, respectively. Hyperkinesia was the most frequent category of EPS-related adverse events in this study, and was reported at a similar rate between the placebo (4.9%) and INVEGA® SUSTENNATM 234/234 mg (5.5%) groups, but at a lower rate in the 234/39 mg group (1.3%).

Dystonia: *Class Effect*: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Laboratory Test Abnormalities: In the pooled data from the two double-blind, placebo-controlled, 13-week, fixed-dose trials, a between-group comparison revealed no medically important differences between INVEGA[®] SUSTENNA[™] and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA[®] SUSTENNA[™] and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA[®] SUSTENNA[™] was associated with increases in serum prolactin [see Warnings and Precautions]. The results from the 13-week study involving 234 mg initiation dosing, the 9-week, fixed-dose, double-blind, placebo-controlled trial, and the double-blind phase of the maintenance trial exhibited comparable findings.

Pain Assessment and Local Injection Site Reactions: In the pooled data from the two 13-week, fixed-dose, double-blind, placebo-controlled trials, the mean intensity of injection pain reported by subjects using a visual analog scale (0 = no pain to 100 = unbearably painful) decreased in all treatment groups from the first to the last injection (placebo: 10.9 to 9.8; 39 mg: 10.3 to 7.7; 78 mg: 10.0 to 9.2; 156 mg: 11.1 to 8.9). The results from both the 9-week, fixed-dose, double-blind, placebo-controlled trial and the double-blind phase of the maintenance trial exhibited comparable findings.

In the 13-week study involving 234 mg initiation dosing, occurrences of induration, redness, or swelling, as assessed by blinded study personnel, were infrequent, generally mild, decreased over time, and similar in incidence between the INVEGA® SUSTENNA™ and placebo groups. Investigator ratings of injection pain were similar for the placebo and INVEGA® SUSTENNA™ groups. Investigator evaluations of the injection site after the first injection for redness, swelling, induration, and pain were rated as absent for 69-100% of subjects in both the INVEGA® SUSTENNA™ and placebo groups. At Day 92, investigators rated absence of redness, swelling, induration, and pain in 95-100% of subjects in both the INVEGA® SUSTENNA™ and placebo groups.

Adverse Reactions Reported With Oral Paliperidone: The following is a list of additional adverse reactions that have been reported with oral paliperidone in subjects with schizophrenia: Cardiac disorders: atrioventricular block first degree, palpitations, sinus arrhythmia Gastrointestinal disorders: abdominal pain, swollen tongue

General disorders and administration site conditions: edema

Immune system disorders: anaphylactic reaction

Musculoskeletal and connective tissue disorders: muscle rigidity

Nervous system disorders: tremor

Reproductive system and breast disorders: priapism, breast discharge Vascular disorders: ischemia

Adverse Reactions Reported With Risperidone: Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with oral risperidone and risperidone long-acting injection can be found in the ADVERSE REACTIONS sections of the package inserts for those products.

DRUG INTERACTIONS

Since paliperidone palmitate is hydrolyzed to paliperidone *[see Clinical Pharmacology (12.3) in full PI*], results from studies with oral paliperidone should be taken into consideration when assessing drug-drug interaction potential.

Potential for INVEGA[®] SUSTENNA™ to Affect Other Drugs: Given the primary CNS effects of paliperidone *[see Adverse Reactions]*, INVEGA[®] SUSTENNA™ should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopamine agonists.

Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA® SUSTENNA™ is administered with other therapeutic agents that have this potential *[see Warnings and Precautions]*.

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. *In vitro* studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.

Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No *in vivo* data are available and the clinical relevance is unknown.

Potential for Other Drugs to Affect INVEGA® SUSTENNA™: Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While *in vitro* studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, *in vivo* studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. *In vitro* studies how of total body clearance. *In vitro* studies have shown that paliperidone is a P-qp substrate.

Co-administration of oral paliperidone extended release once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state C_{max} and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of INVEGA® SUSTENNATM should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA® SUSTENNATM should be re-evaluated and decreased if necessary.

Paliperidone is metabolized to a limited extent by CYP2D6 *[see Clinical Pharmacology (12.3) in full PI]*. In an interaction study in healthy subjects in which a single 3 mg dose of oral paliperidone extended release was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.

Co-administration of a single dose of an oral paliperidone extended-release 12 mg tablet with divalproex sodium extended-release tablets (two 500 mg tablets once daily at steady-state) resulted in an increase of approximately 50% in the C_{max} and AUC of paliperidone. Although this interaction has not been studied with INVEGA® SUSTENNATM, a clinically significant interaction would not be expected between divalproex sodium and INVEGA® SUSTENNATM intramuscular injection.

USE IN SPECIFIC POPULATIONS

Pregnancy: Pregnancy Category C.: There were no treatment-related effects on the offspring when pregnant rats were injected intramuscularly with paliperidone palmitate during the period of organogenesis at doses up to 160 mg/kg, which is 10 times the maximum recommended human 234 mg dose of INVEGA® SUSTENNATM on a mg/m² basis.

In studies in pregnant rats and rabbits in which paliperidone was given orally during the period of organogenesis, there were no increases in fetal abnormalities up to the highest doses tested (10 mg/kg/day in rats and 5 mg/kg/day in rabbits, which are each 8 times the maximum recommended human dose [12 mg/day] of orally administered paliperidone [INVEGA®] on a mg/m² basis).

In rat reproduction studies with risperidone, which is extensively converted to paliperidone in rats and humans, increases in pup deaths were seen at oral doses which are less than the maximum recommended human dose of risperidone on a mg/m² basis (see RISPERDAL[®] package insert).

There are no adequate and well controlled studies of INVEGA[®] SUSTENNA[™] in pregnant women. INVEGA[®] SUSTENNA[™] should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Use of first generation antipsychotic drugs during the last trimester of pregnancy has been associated with extrapyramidal symptoms in the neonate. These symptoms are usually self-limited. It is not known whether paliperidone, when taken near the end of pregnancy, will lead to similar neonatal signs and symptoms. Labor and Delivery: The effect of INVEGA[®] SUSTENNA[™] on labor and delivery in humans is unknown.

Nursing Mothers: In animal studies with paliperidone and in human studies with risperidone, paliperidone was excreted in the milk. Therefore, women receiving INVEGA® SUSTENNA™ should not breast feed infants.

Pediatric Use: Safety and effectiveness of INVEGA® SUSTENNATM in patients < 18 years of age have not been established.

Geriatric Use: Clinical studies of INVEGA® SUSTENNA™ did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with renal impairment [see Clinical Pharmacology (12.3) in full PI], who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.5) in full PI].

Renal Impairment: INVEGA® SUSTENNA[™] has not been systematically studied in patients with renal impairment [see Clinical Pharmacology (12.3) in full PI]. For patients with mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min), recommended initiation of INVEGA® SUSTENNA[™] is with a dose of 156 mg on treatment day 1 and 117 mg one week later, both administered in the deltoid muscle. Thereafter, follow with monthly injections of 78 mg in either the deltoid or gluteal muscle.

INVEGA[®] SUSTENNA[™] is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min).

Hepatic Impairment: INVEGA® SUSTENNA™ has not been studied in patients with hepatic impairment. Based on a study with oral paliperidone, no dose adjustment is required in patients with mild or moderate hepatic impairment. Paliperidone has not been studied in patients with severe hepatic impairment.

DRUG ABUSE AND DEPENDENCE

Controlled Substance: $\mathsf{INVEGA}^{\otimes}$ SUSTENNATM (paliperidone) is not a controlled substance.

Abuse: Paliperidone has not been systematically studied in animals or humans for its potential for abuse.

Dependence: Paliperidone has not been systematically studied in animals or humans for its potential for tolerance or physical dependence.

OVERDOSAGE

Human Experience: No cases of overdose were reported in premarketing studies with INVEGA® SUSTENNATM. Because INVEGA® SUSTENNATM is to be administered by health care professionals, the potential for overdosage by patients is low.

While experience with paliperidone overdose is limited, among the few cases of overdose reported in premarketing trials with oral paliperidone, the highest estimated ingestion was 405 mg. Observed signs and symptoms included extrapyramidal symptoms and gait unsteadiness. Other potential signs and symptoms include those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, and QT prolongation.

Paliperidone is the major active metabolite of risperidone. Overdose experience reported with risperidone can be found in the OVERDOSAGE section of the risperidone package insert. **Management of Overdosage:** There is no specific antidote to paliperidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consideration should be given to the prolonged-release characteristics of INVEGA® SUSTENNA™ and the long apparent half-life of paliperidone when assessing treatment needs and recovery. Multiple drug involvement should also be considered.

In case of acute overdose, establish and maintain an airway and ensure adequate oxygenation and ventilation. The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of paliperidone. Similarly the alpha-blocking properties of bretylium might be additive to those of paliperidone, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of paliperidone-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Manufactured by:

Janssen Pharmaceutica N.V.

Beerse, Belgium

Manufactured for:


Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Titusville, NJ 08560



Revised: July 2009

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009

36348B



Coming October 2009!

Dulcan's Textbook of Child and Adolescent Psychiatry

Edited by Mina K. Dulcan, M.D.

Special Prepublication Price of 215.00 until October 31, 2009 (thereafter \$239.00)

Dulcan's Textbook of Child and Adolescent Psychiatry supplants the

previous textbook edited by Jerry Wiener and Mina Dulcan—not with a new edition, but rather a new book that offers a fresh look at the field of child mental health. It preserves Wiener's vision of a clinically focused textbook useful to trainees and practitioners in a variety of specialties, providing the most up-to-date and comprehensive text in child and adolescent psychiatry as presented by more than 110 contributors who distill their knowledge and expertise into a single authoritative volume.

Each chapter highlights what we know about evidence-based practices in assessment and treatment, while sections on future research point toward current pressing questions. At the end of each chapter are educational summary points. Of the 65 chapters, 56 feature new lead authors, chosen to represent the expertise of disciplines ranging from pediatrics and neurology to sleep medicine and family therapy.

AMONG ITS KEY FEATURES:

- Chapters on evaluation are developmentally focused, with a separate chapter for each age range.
- The section on diagnosis and assessment has been reconfigured and includes a new chapter on neurological examination and the use of EEG and imaging.
- Eighteen chapters on specific disorders encompass clinical description, diagnosis, epidemiology, comorbidity, etiology, prevention, prognosis, evaluation, treatment approaches, and research directions.
- Special topics include new chapters on bereavement and traumatic grief; ethnic, cultural, and religious issues; aggression and violence; and fundamentals of genetics relevant to child and adolescent psychiatry.

- Additional chapters address special clinical considerations such as children of ill parents AND legal/ethical issues
- Wide-ranging emphasis on treatment—expanded from seven to eighteen chapters—includes psychopharmacology, brain-based innovative treatments, and a spectrum of psychosocial approaches that focus on individual, family, therapeutic milieu, and systemic models of care.
- A new section on consultation provides guidance on interactions with schools, primary care practitioners, and the juvenile justice system.

Scholarly and practical, *Dulcan's Textbook of Child and Adolescent Psychiatry* is a core resource for child and adolescent psychiatry training and will also serve as a reference for practitioners in psychiatry, pediatrics, neurology, psychology, nursing, and social work.



2010 • 1,104 pages • ISBN 978-1-58562-323-5 • Hardcover • Item #62323 Special Prepublication Price of \$215.00 until October 31, 2009 (thereafter \$239.00)

The *First* and *Last* Word in Psychiatry

Order Online: www.appi.org • Toll Free: 1-800-368-5777 Fax: 703-907-1091 • Email: appi@psych.org • Find us on Facebook and Twitter. AH938



Cleveland, Ohio

Chair, Department of Psychiatry

leveland - MetroHealth System, one of the nation's most successful public health systems seeks candidates for the role of Chair. Department of Psychiatry. A major teaching and research affiliate of Case Western Res University School of Medicine since 1914. MetroHealth is comprised of a 731 bed major medical center, a rehabilitation hospital, two long term care/skilled nursing centers, an outpatient surgery center and a network of community based healthcare centers. Metro Medical Center, a magnet status hospital offers the most advanced techniques in treating complex medical problems and is one of the premier comprehensive healthcare providers in Northeast Ohio.

The new chair will oversee the provision of psychiatric services and lead the department in recruitment of physicians and other clinical professionals. He/she will collaborate with clinical leaders and administration at MetroHealth in defining, developing and implementing strategy for psychiatric programs. The chair will be expected to enhance the department by strengthening its research, education and programmatic initiatives.

The successful candidate will be an outstanding clinician and respected academic leader with demonstrated ability to effectively inspire, recruit, manage and mentor students, residents and faculty. He/she should demonstrate an understanding of the importance of clinical outcomes, investigation, and teaching in a patient driven service culture to the success of a modern teaching and academic psychiatry department. Candidates will need to have a distinguished track record of clinical and professional accomplishments in the psychiatry field and be eligible for an appointment at the associate professor level or higher at Case Western Reserve University School of Medicine.

Nominations, inquires and expressions of interest should be directed to Christine Mackey-Ross or Linda Komnick at Witt/Kieffer, lindak@wittkieffer.com or (847)-304-8754

"In employment, as in education, MetroHealth System, an affiliate of Case Western Reserve University School of Medicine is committed to Equal **Opportunity and Diversity.**



Life is better for Psychiatrists in Kamloops and Penticton, British Columbia, Canada



betterhere.ca

Here's Why...

Whether you are looking to improve your golf game, longing to hit the trails or looking for cultural enrichment, you can work and enjoy our exceptional four-season playground all in the same day. Enjoy the advantages of a less hurried lifestyle while and the urban amenities available in Kamloops and Penticton BC.

Psychiatrist candidates are eligible for funded recruitment visits and relocation support. Eligibility Canadian Royal College Fellowship (e.g., American Boards) required.

Contact us today and find out why it's better here.

Pentict	on Kamloc	ps Penticton	Kamloops
betterhere.ca	I-877-522-9722	physicianrecruitme	ent@interiorhealth.ca
	<u>نې</u>	Interior Health	



Department of Veterans Affairs

Director of Residency Training Harvard South Shore Psychiatry Residency Training Program Department of Psychiatry Harvard Medical School

The VA Boston Healthcare System

Harvard Medical School and the VA Boston Healthcare System are recruiting a Training Director for the Harvard South Shore Psychiatry Residency Training Program (HSS). The Harvard Department of Psychiatry at the VA Boston Healthcare System has undergone a major expansion of teaching, research, and academic clinical programming over the past two years. The current Training Director is assuming the duties of Departmental Chair for Academic Development, which will include ongoing support to HSS including teaching, supervision, and consultative support to the incoming Training Director.

HSS is a consortium program affiliated with Harvard Medical School and sponsored by the VA Boston Healthcare System. Residents rotate among three Boston VA campuses, other Harvard-affiliated training hospitals, and Massachusetts Department of Mental Health facilities. HSS receives stable funding for 32 PGY I-IV resident positions plus ample administrative support, not dependent on GME pass-through funding. Major foci of program excellence include biopsychosocial assessment and interviewing skills, academic development in research, teaching and leadership, evidence-based pharmacotherapy, and manual-guided psychotherapies. Comprehensive program description can be found at www.harvardsouthshorepsychiatry.org.

The competitive Training Director candidate will have strong academic credentials, residency administration experience at the site or program level, and dem-onstrated scholarly ability in a relevant field. The applicant must be boardcertified in psychiatry with a minimum of 5 years of post-residency experience, and is expected to qualify for a Harvard Medical School appointment at the Assistant or Associate Professor level.

This position offers a highly competitive federal salary and benefits. VA Boston is an Affirmative Action / Equal Opportunity Employer, and women and indi-viduals from health-underserved minority populations are encouraged to apply. To apply, candidates should send a letter of interest, CV, and the names of three persons to contact for references to

Drs. Mark Bauer & Gary Kaplan, Search Committee Co-Chairs 940 Belmont Street, Brockton, MA 02301; or email materials to: Eugene.Francois@va.gov with a copy to vhabhsjobs@med.va.gov

SERVING THOSE WHO HAVE SERVED OUR COUNTRY

Coatesville VA Medical Center

State of the Art Mental Health Facility Board Eligible or Board Certified Psychiatrists

Psychiatrists:

- Work with a multi-disciplinary team
- Are eligible for annual performance awards up to 7.5% of annual salary
- Receive excellent benefits package **Coatesville Veterans Affairs**

Medical Center:

If you are interested in sharing your skills and your passion to care

for Veterans at Coatesville VA Medical Center, please forward your curriculum vitae to:

- Provides acute and chronic care for patients with all forms of major psychiatric disorders
- Is affiliated with local medical school
- Is located in a beautiful setting, close to Philadelphia and other points of interest
- For details of job duties, visit our website: http://www.coatesville.va.gov/careers Vacancy MPA #19, FY'09

Coatesville VA Medical Center (11D) 1400 Blackhorse Hill Road, Coatesville, PA 19320 Attn: Ken Whitehall, AO/COS Fax: 610-380-4391

Patient Centered

Care Focused



Assistant Medical Director Behavioral Health – Inpatient Care

HealthPartners Medical Group is a top multi-specialty group based in Minneapolis/St. Paul, Minnesota. Regions Hospital is our busy NAMI "Provider of the Year" hospital in St. Paul, home to our ER-based short-stay psychiatric unit and inpatient psychiatric facilities.

We are recruiting for an Inpatient Behavioral Health Medical Director at Regions Hospital. In addition to maintaining substantive patient care responsibilities, this consensus-building leader will measure and improve quality of inpatient psychiatric care and patient flow; oversee our Psychiatric Consultation & Liaison Service; engage and supervise Regions Hospital inpatient psychiatrists, moonlighters and Advanced Practice Providers; develop and implement inpatient mental health policies/procedures; and ensure hospital regulatory requirements are met (JCAHO, CMS, MN DMS, etc.). In addition, there will be a substantial role with our psychiatric residents, medical students and NP/PA fellows.

Qualified candidates will have at least two (2) years' experience leading and motivating hospital-based Inpatient Behavioral Health care teams, and at least five (5) years' recent inpatient practice experience. Board Certification in Psychiatry and active, valid MN medical licensure are required. We offer a competitive compensation and benefits package, paid malpractice coverage and a rewarding work environment.

Meet with Dr. Michael Trangle, Associate Medical Director, during the Institute on Psychiatric Services (IPS) Conference, October 8-11, in New York. To make arrangements, please forward your CV and cover letter to: **lori.m.fake@ healthpartners.com** or call (800) 472-4695 x1. Apply online at **www.healthpartners.jobs**. EOE

Medical Group

w w w.healthpartners.com w w w.regionshospital.com

Enjoy Quality of Life...Practice Quality Medicine...

McLeod Health Behavioral Health Psychiatric Center is located in the beautiful southern town of Darlington, SC- a quick 45 minute drive to our state capital, Columbia, SC, and a 2 Hour drive to Charleston, SC and Charlotte, NC. We are looking for two BC/BE Psychiatrists with an innovative approach to medicine. Duties will include inpatient, outpatient, and Consult Services. Depending on the Physician's strengths, the Physician will perform any combination of these duties. Other features of the position include:

Flexible schedule with limited call

New state of the art facility with 23 inpatient beds

24 hour Access Center with an experienced staff

Great potential for program growth and development

We offer a competitive salary, comprehensive benefits and retirement package, paid time off, paid professional liability insurance, CME allowance, relocation assistance, and sign on bonus.

McLeod is a leader in the healthcare industry. We are committed to developing patient-centered, evidence-based, physician-led, quality health care in a not-for-profit hospital system that values each individual patient.

Don't miss an opportunity to become a staff physician with a leader in healthcare! Please contact Tiffany Ellington, Director of Physician Recruitment, at mcleodphysicianrecruiting.org or 843-777-5169.



DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER DAYTON, OHIO

The Dayton Veterans Affairs Medical Center (VAMC), in collaboration with Wright State University Boonshoft School of Medicine in Dayton, Ohio, seeks a **Medical Director (Opiate Treatment Program)**, full-time **Psychiatrists**, and one part-time **Psychiatrist (Dual Diagnosis)**, to provide direct patient care in both the residential and outpatient settings. The incumbents must be well versed in the major treatment modalities for diagnosing and treating a wide variety of psychiatric disorders in Veterans. The Medical Center is a 539-bed multi-specialty Dean's Committee Hospital.

Applicants should be board-certified or board eligible. Graduating residents and fellows may apply; have a license from one of the 50 states; and be a citizen or permanent resident or the USA.

Dayton VAMC employees enjoy excellent federal benefits and competitive salaries.

Dayton, the birthplace of flight, is located in the beautiful rolling hills of Southwestern Ohio and offers the convenience of a city, without the hassles. The metropolitan area has five universities, excellent school systems, museums, theaters, and other recreational opportunities, and is the home of Wright-Patterson Air Force Base.

- Dayton VAMC employees enjoy excellent federal benefits and competitive salaries.
- Recruitment incentive and moving/relocation expenses may be authorized.
 Medical Malpractice Claims coverage is provided under the Federal Tort Claims Act.
- The Dayton VA Medical Center has active affiliations with the Wright State University Boonshoft School of Medicine and the School of Professional Psychology.
- Faculty positions and resident teaching opportunities are available at the Wright State University Boonshoft School of Medicine.

Send curriculum vitae with three references to:

Dave Drew, Acting Chief Mental Health Service, Dayton VA Medical Center Mental Health Service, 4100 West Third Street, Dayton, OH 45428 E-mail: Dave.Drew@va.gov, Tel: 937-268-6511, ext. 2667, Fax: 937-267-3924

The VA is an Equal Opportunity Employer



Department of Veterans Affairs

Psychiatrists - VA Boston Healthcare System

The VA Boston Healthcare System (VABHS) is recruiting academically oriented psychiatrists for a number of key positions in our growing Mental Health Service, which has strong and longstanding affiliations with Harvard Medical School (HMS) and Boston University School of Medicine (BUSM) VABHS is a New England regional referral center for veterans' health care.

Medical Director, Consultation-Liaison Psychiatry West Roxbury Campus:

VABHS is seeking a Medical Director for the Psychiatry Consultation-Liaison service, West Roxbury campus. We seek a board certified academic psychiatrist with at least 5 years' post-residency experience full time (or equivalent) on an academic C-L service, demonstrated excellence in clinical teaching, strong administrative skills, and the motivation and ability to lead this outstanding clinical teaching service. The C-L service receives more than 1000 consultation requests per year, and is an integral part of a vibrant and exceptional academic environment that features nationally recognized training and research programs, and several VA Clinical Centers of Excellence. Academic appointment is through HMS, commensurate with qualifications. The Medical Firector oversees the VA-Brigham Women's Hospital Psychosomatic Fellowship and BUSM and HMS resident and medical student C-L rotations.

Psychiatrist with expertise in PTSD and treatment for Returning Veterans – Brockton Campus:

VABHS is recruiting a full-time board-certified (board eligible if less than 2 years post-residency) psychiatrist with psychiatric expertise in the treatment of emotional trauma. This position is divided evenly between inpatient and outpatient programs. In the inpatient role, the candidate will join a well-staffed multidisciplinary inpatient treatment team to provide direct clinical services to Returning Veterans or veterans with PTSD. In the outpatient role, the candidate will join a vibrant multidisciplinary PTSD and Center for Returning Veterans treatment team that provides evidence-based clinical care to veterans of all eras including a large cohort of veterans who have recently returned from Iraq and Afghanistan. Duties include support of the academic mission of the medical center, including supervision of psychiatry residents and the opportunity to participate in teaching and research. This position offers a faculty appointment at Harvard Medical School commensurate with experience.

Outpatient Psychiatrist

Jamaica Plain and Causeway Campuses:

We are seeking a full-time board-certified (board eligible if less than 2 years post-residency) psychiatrist in outpatient care at our Jamaica Plain and Causeway campuses. In this role, the candidate will join a vibrant multidisciplinary PTSD and Center for Returning Veterans treatment team that provides evidence-based clinical care to veterans of all eras including Returning Veterans. The candidate will also join an active teaching oriented team involved in the treatment of schizophrenia. There is a significant role for this psychiatrist in the training and supervision of residents and there is the po-tential to collaborate in clinical research. This position offers a faculty appoint-ment at Boston University School of Medicine commensurate with experience.

The above positions offer a highly competitive VA salary and exist in an outstanding academic environment with prominent teaching and research programs.


Please send a letter of interest, CV, and contact information for three references to: Gary Kaplan, MD, Director, Mental Health Service, VA Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301. Phone: 774-826-2473; email: Gary.Kaplan@va.gov with a copy to vhabhsjobs@med.va.gov

Emergency Department Moonlighting Positions Brockton Campus:

VABHS is recruiting board certified (board eligible if less than 5 years postresidency) psychiatrists to provide direct clinical services and clinical supervision of psychiatry residents on evenings and weekends in the Urgent Care Department on our Brockton campus. This position offers competitive compensation and the possibility of an academic appointment for qualified individuals. Hours are 4pm-11pm weekdays and 7am-3pm or 3pm-11pm on Saturdays and Sundays.

Please send a letter of interest, CV, and contact information for three references to: Ronald Gurrera, MD, Director of Urgent Care Services, Mental Health Service, VA Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301. Phone: 774-826-2473; email: Ronald.Gurrera@va.gov with a copy to vhabhsjobs@med.va.gov.

VA Boston is an Affirmative Action/Equal Opportunity Employer with a strong institutional commitment to diversity in all areas. These positions will be filled without discrimination. You must be a U.S. citizen to apply.



Practice innovative psychiatry in a world class system.

As a VA psychiatrist, you'll be part of an interdisciplinary care team driven to develop innovative approaches to mental health care. You'll translate scientific evidence into daily practice as you tackle one of today's most timely issues - helping America's Veterans reclaim their mental health.

- · Practice model based on care needs, not insurance company regulations
- Diverse professional opportunities
- Computerized Patient Record System
- · One license/50 states
- · Paid medical liability coverage
- · Stable health and retirement benefits
- Exceptional education support
- opportunities (subject to funding availability) · 26 days annual paid vacation

Hiring Veterans and non-Veterans

Department of Veterans Affairs An Equal Opportunity Employer

Apply today at www.VAcareers.va.gov/MHP or call 1-800-949-0002

Mental Health Care Professionals Psychiatrists/Psychologists/Social Workers

Clinical Nurse Specialists/Addiction Therapists

Join VA Northern California Health Care System's (NCHCS) mental health care team and support America's heroes. NCHCS is now hiring mental health care professionals to be part of our interdisciplinary care team; you'll treat patients struggling with the full range of emotional and mental disorders, including PTSD, traumatic brain injuries, mood disorders, substance abuse disorders, and sexual trauma. You'll work in an environment where innovation is encouraged, and scientific evidence directs our practice.

We are now hiring for full and part time positions in Sacramento, Fairfield, Redding and Chico. Call today and be a part of VA's Mental Health Enhancement Initiative.

- Interdisciplinary care team model of practice
- Practice model is based on care needs, not insurance company regulations
- Your out of state license allows you to practice at any of our facilities
- Diverse professional opportunities clinical, leadership, research, education, and national policy development
- Salary is competitive and based on credentials and experience
- Exceptional paid time off package
- Excellent health and retirement benefits
- Student loan reimbursement of up to \$38,000 for psychiatrists, psychologists and psychiatric nurses

Please email Erica Settlemyer, Human Resources Specialist at erica.settlemyer@va.gov

Department of Veterans Affairs is an Equal Opportunity Employer

ATASCADERO STATE HOSPITAL BE/BC Psychiatrist

Atascadero State Hospital now pays board certified psychiatrists starting at \$223,464 and advancing stepwise to \$255,732. Atascadero is the nation's premier center for the treatment of forensically committed mentally ill patients. Our hospital is a teaching site affiliated with the University of California, accredited by JCAHO, and recipient of the prestigious Codman Award. All of our psychiatrists are board eligible and most are board certified. Many of our psychiatrists have forensic subspecialty boards.

We are located midway between San Francisco and Los Angeles on the scenic central California Coast, south of Big Sur. We offer a spectacularly beautiful environment in San Luis Obispo County with temperate climate, beaches, world class wineries, cultural activities, golfing, sailing, riding, clean air, and excellent schools through the University level.

Our benefit package is valued at an additional 30%, which includes retirement plans (including safety retirement), health plans, professional liability coverage, paid holidays, educational leave, and generous annual leave. On-call duty is compensated hour for hour over and above the base salary. Applicants must hold a current California license, or have pending application with the Medical Board of California.

For a prompt and confidential review, send CV to:

Jeanne Garcia, M.D. P. O. Box 7001 Atascadero, CA 93423-7001 (805) 468-2005 or fax (805) 468-2138 or e-mail us: jeanne.garcia@ash.dmh.ca.gov

WE ARE AN EQUAL OPPORTUNITY EMPLOYER.

Professor or Associate Professor of Autism

Harvard Medical School and Director of the Lurie Family Autism Center at Massachusetts General Hospital

Massachusetts General Hospital and Harvard Medical School are jointly seeking a clinical, academic and scientific leader to fill the position of Professor or Associate Professor in the field of Autism at Harvard Medical School and Director of the Lurie Family Autism Center at Massachusetts General Hospital

We are seeking an outstanding clinician, investigator, and teacher who is a distinguished national and international leader in autism. Expertise in leading a complex clinical, research and academic center is imperative. She/he should have a strong vision for achieving excellence in a multi-disciplinary autism center encompassing clinical care, scientific investigation, policy development and advocacy, and training, and an understanding of the opportunities, challenges and special requirements of working within a large academic medical center. Organizational, fiscal, fundraising and interpersonal skills are essential. Candidates should have received an M.D., PhD, or M.D. /Ph.D. degree and be Board Certified in their specialty. Academic credentials should be of sufficient strength to warrant appointment as Professor or Associate Professor at Harvard Medical School.

Interested individuals should send a letter of application and current CV in hard copy and electronic format to:

Ronald E. Kleinman, MD Chair, ad hoc Search Committee for Director of the Lurie Family Autism Center Chief of Pediatrics, Massachusetts General Hospital 55 Fruit Street, Boston, MA 02114 rkleinman@partners.org

Harvard Medical School and Partners Healthcare System are equal opportunity/affirmative action employers with strong institutional commitments to diversity in their faculty. Women and minority candidates are particularly encouraged to apply.



VA LONG BEACH



A Division of VA Desert Pacific

VA Long Beach Healthcare System is seeking two board certified or board eligible psychiatrists to provide outpatient care who demonstrate excellent clinical care and the ability to work collaboratively with other mental health and primary care providers. Competitive salary, depending on qualifications, with competitive benefits and recruitment incentives are possible. The Veterans Administration is an Equal Opportunity Employer.

To find out more about this exciting opportunity contact:

Larry Albers, MD, Chief of Mental Health larry.albers@va.gov 562-826-5758

APA Member Benefits and Services That Make a Difference

- Bank of America Credit Cards and Financial Tools — Earn WorldPoints[™] Rewards
- APA Job Bank Online career search and recruitment
- The Psychiatrists' Program Medical malpractice insurance for psychiatrists
- Car Rentals Substantial discounts from Alamo, Avis, Budget, Hertz, or National
- Solveras Payment Systems Affordable tools to effectively manage patient payments
- Magazine Subscriptions Save up to 50% off regular subscription rates on magazines
- Retirement and Investment Planning Meet your short and long-term retirement and financial planning goals
- Legal Consultation Find money-saving legal advice with APA's Legal Consultation Plan

Learn more about these benefits and savings at www.psych.org/members corner



Questions? Contact APA Answer Center Call Toll-Free: 1-888-35-PSYCH From outside the U.S. and Canada call: 1-703-907-7300 Email: apa@psych.org

Index to Advertisers October 2009

The publication of an advertisement in this journal does not imply endorsement of the product or service by the American Psychiatric Association.

Employment OpportunitiesA31-A34			
Janssen Pharmaceutica Invega C2-A6			
Invega Sustenna A22-A27			
MIT PressA13			
Montefiore Medical Center A1			
The Osler Institute A			
U.S. Pharmaceuticals, Pfizer Inc. GeodonA17-A18			
UCB Pharma			
VenlafaxineA36-C4			
University of Pittsburgh Medical CenterA21			

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901. Subscriptions (per year): individual \$205.00, international \$308.00. For additional subscription options, including single issues and student rates, please contact Customer Service at 1-800-368-5777 or email appi@psych.org. Institutional subscriptions are tier priced. For institutional site license or pricing information, contact Customer Service or visit http:// highwire.stanford.edu/tfocis/.

Business communications, address changes, and subscription questions from APA members should be directed to the Division of Member Services: (888) 35-PSYCH (tollfree). Nonmember subscribers should call the Circulation Department (800) 368-5777. Author inquiries should be directed to the Journal editorial office: (703) 907-7885 or (703) 907-7884; fax (703) 907-1096; e-mail ajp@psych.org.

Business Management: Nancy Frey, Director, Publishing Services; Laura G. Abedi, Associate Director, Production; Alison Jones, Advertising Prepress Manager; Robert Pursell, Director, Sales and Marketing.

Pharmaceutical Print Advertising: Frank Cox, Kathleen Harrison, Valentin Torres, Pharmaceutical Media, Inc. 30 East 33rd Street, New York, NY 10016. (212) 685-5010; fax (212) 685-6126; e-mail vtorres@pminy.com.

Nonpharmaceutical and Online Sales: Brian Skepton, (703) 907-7332; e-mail bskepton@psych.org.

Pages are produced using Adobe FrameMaker+ SGML 6.0. Printed by RR Donnelley, Mendota, IL., on acid-free paper effective with Volume 164, Number 11, November 2007.

Periodicals postage paid at Arlington, VA, and additional mailing offices. POSTMASTER: Send address changes to The American Journal of Psychiatry, Circulation Department, American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

The American Psychiatric Association does not hold itself responsible for statements made in its publications by contributors or advertisers. Unless so stated, material in The American Journal of Psychiatry does not reflect the endorsement, official attitude, or position of the American Psychiatric Association or of the Journal's Editorial Board.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the American Psychiatric Association for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400 (tel), (978) 646-8600 (fax), www.copyright. com (web site). 0002-953X/05/\$15.00.

This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Requests for commercial distribution should be directed to (703) 907-7894. APA does not require that permission be obtained for the photocopying of isolated articles for nonprofit classroom or library reserve use; all fees associated with such permission are waived.

Copyright © 2009 American Psychiatric Association.

BRIEF SUMMARY. See package insert for full Prescribing Information. For further product information and current package insert, please visit www.VERTablets.com or call our medical communications department toll-free at 1-888-299-1053.

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Venlataxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the balance this risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 or older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Venlafaxine Extended Release Tablets are not approved for use in exolution to the fore Memiren and Researching and Roticat Courseling Information for use in pediatric patients. [See Warnings and Precautions and Patient Counseling Info in the full Prescribing Information.]

INDICATIONS AND USAGE: Veniafaxine Extended Release Tablets (veniafaxine hydrochloride) are indicated for the treatment of major depressive disorder (MDD) and Social Anxiety Disorder (SAD), also known as Social Phobia, as defined by DSM-IV. Efficacy of veniafaxine in MDD was shown in both short-term trials and a longer-term trial. Efficacy in SAD was established in short-term trials. **CONTRAINDICATIONS:** Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) [see Warnings and Precautions, Potential for interaction with Monoamine Oxidase inhibitors]. **WARNINGS AND PRECAUTIONS:** Clinical Worsening and Suicide Risk: Patients with UDD beth education and their deprecautions of their deprecision ender the amergement of the inferencement of the amergement of the amergement of the inferencement of the inference MDD, both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressant such a build be in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase short-emr placebo controlled trials of anludepressant drugs (SSRIs and others) showed that these ortugs increases the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents and young adults (ages 18-24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive-compulsive disorder, or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median divartion of 2 months) of 11 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders. There are considerable variation in rick duration of 2 months) of 11 antidepressant fungs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications. No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence succeasity risk exteriors to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indications should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiely, adjuttion, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and exclicitation attacked with addited with additecoursents for MDD as well as for the been reported in adult and pediatric patients being treated with antidepressants for MDD as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there and characteristic waves in a solution of the possibility of the solution in plates in a following of the possibility of the solution in plates in a following of the plates and the solution of the solution preclavor of or solution of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuution can be associated with certain symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) in the full prescribing information for a description of the risks of discontinuation of Ventataxine Extended-Release Tables, Families and caregivers of patients being treated with antidepressants for MDD or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Venlataxine Extended Release Tablets should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. **Potential for Interaction** With Monoamine Oxidase Inhibitors: Adverse reactions, some serious, have been reported in patients who recently discontinued an MAOI and started on venlafaxine hydrochloride, or who recently discontinued venlafaxine hydrochloride prior to initiation of an MAOI. These reactions included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death. Venlafaxine Extended Release Tablets should not be used in combination with an MAOI, or within at least 14 days of discortinuing treatment with an MAOI. A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (hough not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. It is generally believed (hough not established in controlled trials) that treating such an episode with an antidepressant done may increase the likelihood of precipitation of an wead/manic episode in patients at risk for bipolar disorder. generally benered with the second of precipitation of a mixed rule) for the carries does not plotted with the plotted with an integression of a mixed rule of the second s ond approved for use in treating bipolar depression. **Servotonin Syndrome or Neuroleptic Malignant Syndrome** (NMS)-like Reactions: The development of potentially life-threatening servotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions has been reported with SSRIs and SNRIs alone, including Venlafaxing Mainfant Syndrome (wms)-like reactions has been reported with SSNIs and SMNIs alone, including vehilatabile Extended Release Tablets, but particularly with concomitant use of serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (including MAOIs), with other antipsychotics, or with other dopamine antagonists [see WARNINGS AND PRECAUTIONS in full Prescribing Information]. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms including mental status changes, autonomic instability, neuromuscular aberrations, and/or gastrointestinal symptoms [see Drug Interactions (7. 10]). Serotonin syndrome, in its most severe form can resemble NMS, which includes hypertherming, muscle rigidity. autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. The concomitant use of Venlafaxine Extended Release Tablets with MAOIs is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)]. I concomitant treatment of Venlafaxine Extended Release Tablets with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of Venlataxine Extended Release Tablets with serotonin precursors (such as tryptophan supplements) is not recommended [see Drug Interactions (7.10]]. Treatment with Venlataxine Extended Release Tablets and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the patient develops any symptoms of serotonin syndrome or NMS, and supportive symptomatic treatment should be initiated. **Sustained Hypertension:** Venlatavine hydrochloride is associated with sustained dose-related increases in blood pressure (BP) in some patients, Sustained BP increases could have adverse consequences. Postmarketing cases of elevated BP requiring immediate treatment have been reported. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by BP increases. Preexisting hypertension should be controlled before Venlafaxine Extended Release Tablets therapy is initiated. It is recommended that patients receiving Venlafaxine Extended Release Tablets have regular monitoring of BP. For patients experiencing

sustained increase in BP, either dose reduction or discontinuation should be considered. Elevations in Systolic and Diastolic Blood Pressure (SBP, DBP): In placebo-controlled premarketing studies, there were changes in mean BP. In most indications, a dose-related increase in SBP and DBP was evident. Across all trials, 1.4% of mean bP. In most indications, a dose-related increase in SbP and DbP was evident. Across all mats, 1.4% of patients receiving extended-release ventuaring heydrocholdred experienced a ≥15 mm Hg increase in supine DBP with BP ≥105 mm Hg, compared to 0.9% of patients in the placebo groups. One percent of patients receiving ventaxafine hydrocholdred experienced a ≥20 mm Hg increase in supine SBP with BP ≥180 mm Hg compared to 0.3% of patients in the placebo groups. **Mydriasis:** Mydriasis has been reported in association with ventafaxine hydrocholdred; patients with raised intraocular pressure or patients at risk for acute narrow-angle glaucoma should be monitored. **Discontinuation of Treatment with Ventafaxine Extended Release Tablets:** Discontinuation members here here metaredicable calluded in patients this in validations. In the presenter of the placebo the symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials and retrospective surveys of trials in MDD and SAD. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been associated with the appearance of new symptoms, the frequency of which increased with increased dose level and longer duration of treatment. Reported symptoms include agitation, increased with increased dose level and longer duration of treatment. Reported symptoms include agitation, ancrexia, anxiety, confusion, impaired coordination and halance, diarrhea, dizziness, dyr mouth, dysphoric mood, fasciculation, fatigue, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tinnitus, tremor, vertigo, and vorniting. During marketing of venlafaxine hydrochloride extended-release capsules, other SNRis, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, initiability, and initiation, dizziness, sensory disturbances (e.g., paresthesias), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these reactions are generally self-limiting, there have been reports of serious discontinuation in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following dyspation of the terment, then resymptom symptoms when abrupt, dose or upon discontinuation of treatment. Hen resymptoms have a discontinuition accur following dyspation of the termer dose or upon discontinuation of treatment. Hen resymptoms have reactions are generally ede-gase in the adrupt cessation is recommended whenever possible. If individual symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see Dosage and Administration (2.4) in full prescribing information). Insomnia and Nervousness: Treatment-emergent insomnia and nervousness were more commonly reported for patients treated with venlafaxine hydrochloride extended-release capsules than with placebo in pooled analyses of short-term MDD and other clinical studies, as shown in Table 5 in the full prescribing information. Changes in Weight: In some placebo-controlled trials in MDD, 4% of the patients treated with velocition placebo length of the placebo terret. the patients treated with venlafaxine hydrochloride extended-release capsules and 1% of the placebo-treated patients usualized a loss of 7% or more of body weight during up to 6 months of treatment. The safety and efficacy of venlafaxine therapy in combination with weight loss agents have not been established. Co-administration of Venlafaxine Extended Release Tablets and weight loss agents is not recommended. Venlafaxine Extended Release Veniatavite Extended nelease fabeles and weight loss agents is not recommended. Veniatavite Extended nelease Tablets are not indicated for weight loss alone or in combination with other products. **Changes in Height:** Pediatric Patients: In the six-month, open-label MDD study, children and adolescents had height increases that were less than expected based on data from age- and sex-matched peers. The difference between observed growth rates and expected growth rates was larger for children (<12 years old) than for adolescents [≥12 years old). **Changes in Appetite:** Adult Patients: Treatment-emergent anorexia was more commonly reported for patients treated with veniatavine hydrochloride extended-release capsules than for placebo-treated patients in the pool of short-term, double-blind, placebo-controlled MDD (8% vs 4%) and SAD (20% vs 2%) studies. Pediatric pool or short-term, double-onird, placedo-controlled MUD (8% % 4%) and SAD (20% % 2%) studies. Pediatric Patients: In placebo-controlled trials in MDD and another disorder, 10% of patients aged 6-17 treated with ventafaxine hydrochloride extended-release capsules for up to eight weeks and 3% of patients treated with placebo reported treatment-emergent anorexia. **Activation of Mania/Hypomania**: Mania or hypomania occurred during MDD studies in 0.3% of patients treated with extended release ventafaxine compared with 0% of placebo patients. No reports of mania or hypomania were reported in trials with SAD. As with all drugs effective in the treatment of MDD (veloptice Extended Paleere Tehick abcid be uned antientic in activity in activity with a bittery of monitors). MDD, Venlafaxine Extended Release Tablets should be used cautiously in patients with a history of mania. Hyponatremia: Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including Venlafaxine Extended Release Tablets. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have inappropriate antiduretic hormone secretion (SIAUH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations (8.5) in full prescribing information). Discontinuation of Venlatavine Extended Release Tablets should be considered in patients with symptomatic hyponatremia, and appropriate medical intervention should be instituted. Seizures: In all premarketing venlatavine Extended Release Tablets should be used to 0.3% of venlatavine hydrochloride-treated patients. Venlatavine Extended Release Tablets should be used cautiously in actions with bitters of originate and the bitters of originate medical intervention should be patients with bitters of originate and the bitters of originate and bitters of originate an Vernatavite inplocition de treated patients. Vernatavite Extended in energies faults should be described adultusly in patients with a history of seizures and should be discontinued in any patient who develops seizures. Abnormal Bleeding: SSRis and SNRIs, including Venlatavine Extended Release Tablets, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSADs), warfarin, and other anticoagulants may add to this risk. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Venlatavine Extended Release Tablets and other drugs that affect coagulation. Serum Cholesterol Elevation: Clinically relevant increases in serum cholesterol verse affect coagulation. Serum Cholesterol Elevation: Clinically relevant increases in serum cholesterol were recorded in 5.3% of venklasine hydrocholinde-treated patients and 0.0% of patients receiving placebo for at least 3 months in trials. Measurement of serum cholesterol levels should be considered during long-term treatment. Interstitial Lung Disease and Eosinophilic Pneumonia: Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine-treated patients who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo prompt medical evaluation, and discontinuation of venlafaxine therapy should be considered. Use in Patients with Heart Disease: Premarketing experience with venlafaxine in patients with concomitant systemic illness is limited. Caution is advised in administering Venlafaxine Extended Release Tablets to patients with diseases or conditions that could affect hemodynamic responses. Venlafaxine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from many clinical studies during associated with these dates the streamation streamation and sconting streamations. ventation of the set of a period with these diagnoses were systematically excluded from many clinical studies during ventafaxine's premarketing testing. As increases in heart rate (mean increase of 4 beats per minute in MDD trials and 5 beats per minute in SAD trials) were observed, caution should be exercised in patients whose underlying and 5 beats per internet in SAD trials where observed, califor should be exercised in patients whice interning medical conditions might be compromised by increases in heart rate (e.g., patients with hyperthyroidism, heart failure, or recent myocardial infarction). **ADVERSE REACTIONS: Clinical Studies Experience:** Short-Term, **Placebo-Controlled Trials:** Adverse Events Leading to Discontinuation of Treatment: Approximately 11% of the 357 patients who received veniafaxine hydrochloride extended-release capsules in MDD trials discontinued treatment due to an adverse reaction (vs 6% of the 285 placebo-treated patients). Adverse reactions that led to Approximately 17% of the 277 patients in SAD trials who received veniaxafine hydrochloride extended-release cancel and encontributed to the charge cardial one 6.6% of the 274 placebo-treated patients were treated extended-release cancel and encontributed to the charge cardial one 6.6% of the 274 placebo treated extended developed and the placebo control the total one observe the theory of the 277 patients in SAD trials who received veniaxafine hydrochloride extended developed and the placebo control the total one observe theory one for the 274 placebo treated extended developed theory of the 277 patients in SAD trials who received veniaxafine hydrochloride extended developed and the treatment discontinued to the total observe theory of the 274 placebo treated extended developed theory of the 274 placebo theory of the 274 placebo treated extended developed theory of the 274 placebo theory of theory o capsules discontinued treatment due to an adverse reaction (vs 5% of the 274 placebo-treated patients). Adverse reactions that led to treatment due to an adverse reaction (vs 5% of the 274 placebo-treated patients). Adverse reactions that led to treatment discontinuation in at least 2% of drug-treated patients were nausea, insomnia, impotence, headache, dizziness and somnolence. Adverse Events Occurring at an Incidence of 5% or More: Importe, instability, durantess and sommulate the following adverse reactions that occurred in at least 5% of the patients receiving ventafaxine hydrochloride extended-release capsules and at rate at least twice that of the placebo group of all placebo-controlled trials for the MDD indication (see Table 6): Abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), CNS complaints (dizziness, somnolence, and abnormal dreams), and sweating. In the two U.S. placebo-controlled trials, the following additional reactions occurred in at least 5% of the plateints treated with ventilation hydrochloride extended-release capsules (n = 192) and at a rate at least twice that of the placebo group: Abnormalities of sexual function (importence in men, compared and in verseor, end likelid dereaded, perfortioning amenicative (constitution candidation). (DIS and at a rate at least twice that of the placebo group: Abnormalities of sexual function (impotence in men, anorgasmia in women, and libido decreased), gastrointestinal complaints (constipation and flatulence), CNS complaints (insomnia, nervousness, and tremor), problems of special senses (abnormal vision), cardiovascular effects (hypertension and vasodilatation), and yawning. <u>Social Anxiety Disorder</u>: Note in particular the following adverse reactions that occurred in at least 5% of the patients receiving ventilaxine hydrochloride extended-release capsules and at a rate at least twice that of the placebo group for the 2 placebo-controlled trials for the SAD indication (see Table 7): Asthenia, gastrointestinal complaints (anorexia, constipation, dry mouth, nausea), CNS complaints (dizziness, insomnia, libido decreased, nervousness, somnolence), abnormalities of sexual function (abnorma lejaculation, impotence, libido decreased, nervousness, somnolence), abnormalities of sexual function (abnorma lejaculation, impotence, libido decreased, orgasmic dysfunction), yawn, sweating, and abnormal vision. **Adverse Events Occurring at an Incidence of 2% or Moze:** MDD and SAD trials included patients receiving ventafaxine hydrochloride extended-release capsules in doses ranging from 75 mg to 225 mg/day for up to 12 weeks. The prescriber should be aware that the following adverse reactions figures cannot be used to predict the incidence of adverse reactions in the course of usual medical practice. Similarly, the cited frequencies cannot be compared with figures, botained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescriben physician with some basis for estimating and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to adverse reaction incidence rate in the population studied. [See TABLE 6 in full Prescribing Information] TABLE 6: Treatment Emergent Adverse Reaction Incidence in Short-Term Placebo-Controlled Clinical Trials with Venlafaxine Hydrochloride Extended-Release Capsules in Patients with Major Depressive Disorder. This table reports adverse events that occurred in 2%

or more of patients treated with ventafaxine hydrochloride extended-release capsules where the incidence in patients treated with ventafaxine hydrochloride extended-release capsules (n=357) was greater than the incidence for the respective placebo-treated patients (n=285). For each adverse reaction, the incidence of reactions in the or more of patients treated with venlafaxine hydrochloride extended-release capsules (n=357) was greater than the incidence for the respective placebo-treated patients (n=285). For each adverse reaction, the incidence of reactions in the drug-treated patients is listed before the incidence in placebo-treated patients. **Body as a Whole**: Asthenia (8% and 7%). Cardiovascular System: Vasuea (31% and 7%). Constipation (8% and 5%); Anorexia (8% and 4%); Vomiting (4% and 2%); Hydrension (4% and 4%); Signition (4% and 9%); Somolence (17% and 9%); Constipation (8% and 5%); Anorexia (8% and 4%); Vomiting (4% and 2%); Hydrension (4% and 4%); Somolence (17% and 4%); Isomiting (3% and 1%). **Depression** (3% and 4%); Paresthesia (3% and 1%); Abnormal Dreams (7% and 2%); Thernor (5% and 2%); Depression (3% and 4%); Paresthesia (3% and 1%); Libido Decreased (3% and <1%); Agitation (3% and 1%). **Respiratory System**: Pharyngitis (7% and 6%); Yawn (3% and 0%). **Siven:** Short-Term Placebo-Controlled Clinical Trials with Venlafaxine Hydrochloride Extended-felease Capsules in Patients with Social Anxiety Disorder. This table reports adverse events that occurred in 2% or more of patients treated with venlafaxine hydrochloride extended-release capsules where the incidence in patients venlade in lease capsules (17% and 3%); Paresthesia (3% and 1%). See traated patients (n=-274). For each adverse reaction, the incidence of rated of patients (n=-274). For each adverse reaction, the incidence of matients is listed before the incidence in placebo-treated patients (n=-274). For each adverse reaction, the incidence of rated reader (3% and 3%); Cardiovascular (3% and 2%); Diarhee (3% and 3%); Asthenia (17% and 8%); Flu Syndrme (6% and 5%); Anorexia (20% and 3%); Asthenia (17% and 8%); Flu Syndrme (6% and 5%); Accidental Injury (5% and 3%); Abdominal Pain (4% and 3%). Cardiovascular System: Hypertension (5% and 4%); Diarhee (3% and 3%); Cardiovascular (3% and 2%); Diarhee (3% and 3%); Cardiovascular (3% and 2%); Diarhee (3% and 3%); Cardiovasc drog exposure. These reports include the following reactions: agranulous to standard and the following reactions: agranulous to the fol delirium, EKG abnormalities such as QT prolongation; cardiac arrhythmias including artial fibrillation, supraventricular tachycardia, ventricular extrasystoles, and rare reports of ventricular fibrillation and ventricular tachycardia, including torsade de pointes; epidermal necrolysis/Stevens-Johnson syndrome, erythema multiforme, extrapyramidal symptoms (including dyskinesia and tardive dyskinesia), angle-closure glaucoma, hemorthage (including ye and gastroitestinal bleeding), hepatic reactions (including GE elevation; abnormalities of unspecified liver function tests; liver damage, necrosis, or failure; and fatty liver), interstitul lung disease, involuntary movements, LDH increased, neutropenia, night sweats, pancreatits, pancrytopenia, panic, prolactin increased, renal failure, rhabdomyolysis, serotonin syndrome, shock-like electrical sensations or tinnitus (in some cases, subsequent to the discontinuation of ventiafaxine or tapering of dose), and syndrome of inappropriate antiduretic hormone secretion (usually in the elderly). **DRUG INTERACTIONS:** Alcohol: The effect of alcohol on plasma levels of Ventiafaxine Extended Release Tablets is not known. **Cimetidine:** Use caution when administering ventafaxine hydrocholide with cimetidine to patients with preexisting hypertension or hepatic dysfunction, and the elderly. **Diazepam:** A single dose of diazepam did not appear to affect the PK of either ventafaxine hydrocholide did not have any effect on the PK of diazepam or its active metabolite, desmethyldidazepand or affect the psychomotor and psychometric effects induced by diazepam. **Haloperidol:** Ventafaxine hydrocholide did not have are loss of ther K of either ventafaxine hydrocholide (150 mg/day) decreased total oral-dose clearance of haloperidol. Eventafix the Hydrocholide is and a tribility ound to plasma proteins; coadministration of Ventafaxine Extended Release Tablets and a highly protein-bound drug should not clause increase free concentrations of the other drug. **Drugs Tint Inhibit Cytochrome P450** equipotent, no dosage adjustment is required when veniafaxine hydrochloride is coadministered with a CYP2D6 inhibitor. Pharmacokinetic studies with ketoconazole in both poor and extensive metabolizers of CYP2D6 resulted in higher plasma concentrations and AUCs of both veniafaxine hydrochloride and ODV in most subjects following administration of ketoconazole. Concomitant use of CYP3A4 inhibitors and veniafaxine hydrochloride may increase in higher plasma concentrations and AUCs of both venlafaxine hydrochloride and ODV in most subjects following administration of ketoconazole. Concomitant use of CYP34A inhibitors and venlafaxine hydrochloride may increase levels of both venlafaxine hydrochloride and ODV. Use caution if therapy includes venlafaxine hydrochloride and any CYP3A4 inhibitor. **Drugs Metabolized by Cytochrome P450 Iscenzymes:** Venlafaxine hydrochloride is a relatively weak inhibitor of CYP2D6 in vitro. Imipramine: Venlafaxine hydrochloride is a presence of venlafaxine hydrochloride. The 2-OH-desipramine AUCS (nerseased by 2-bott) 35% in the presence of venlafaxine hydrochloride. The 2-OH-desipramine AUCS increased by 2-bott 35% in the presence of venlafaxine hydrochloride. The 2-OH-desipramine AUCS increased by 2-bott 4-5 fold (with venlafaxine hydrochloride doses of up to 75 mg q 12h). The clinical significance of elevated 2-OH-desipramine is unknown. Imipramine did not affect the PK of venlafaxine hydrochloride and ODV. Metoproloi. Venlafaxine hydrochloride (50 mg/day) in one study. Caution should be exercised to reduce the blood-lowering effect of metoproloi (100 mg q 2A htor 5 days) in one study. Caution should be exercised when these drugs are given together. Risperidone: Venlafaxine hydrochloride (50 mg/day) isightly inhibited metabolism of a single 1-mg dose of risperidone, resulting in an about 32% increase in risperidone AUC. Venlafaxine hydrochloride cadministration did not significantly after the PK profile of the total active molety (risperidone plus its metabolite 9-hydroxyrisperidone). CYP3A4: Venlafaxine hydrochloride (150 mg/day) resulted in a 28% decrease in the AUC of a single dose of a single 800-mg dose of indinavir and 36% decrease in indinavir (2MIANDICATIONS and WARNIWGS AND PRECAUTIONS in full Prescribing Information.] **Other CNS**-**Active Drugs:** Caution is advised if there is concomitant use of venlafaxine hydrochloride did not inhibit CYP2C9 in vitro. In vivo, venlafaxine hydrochloride 75 mg cardinicities of which other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. John's Wort. If concomitant treatment of Venlafaxine Extended Release Tablets with these drugs is warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of Veniafaxine Extended Release Tablets with tryptophan supplements is not recommended [see WARNINGS AND PRECAUTIONS in full Prescribing Information]. There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan it concomitant use of Veniafaxine Hydrochloride Extended Release tablets with a triptan is warranted, careful In concommant use or vehicitaxine regulationary during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS in full Prescribing Information). Drugs That Interfere With Hemostasis: Interference with serotonin reuptake may affect platelet function and result in bleeding. Concurrent use of NSADB or aspirin may increase this risk. Increases in prothrombin time (PT), partial thromboplastin time (PT), or INR have been reported when venlafaxine hydrochloride was given to patients on warfarin therapy. Patients on warfarin should be carefully monitored when Venlafaxine Extended Release Tablets are begun or discontinued. Electroconvolusive Therapy: There is no clinical data establishion the benefit of electroconvolusive therapy combined with Venlafavine There is no clinical data establishing the benefit of electroconvulsive therapy combined with Venlafax

Hydrochloride Extended Release Tablets. Postmarketing Spontaneous Drug Interactions, including seizures, tollowing the addition of venlazatine. There have been reports of increases in P1, P11, or INP when venlafazine vasigiven to patients also receiving warfarin. USE IN SPECIFIC POPULATIONS. Pregnancy: Teratogenic Effects:
 Pregnancy Category C. There are no adequate and well-controlled studies of venlafazine in pregnant women. Venlazane bases posed to venlafazine in proceed and venlation of venlafazine pregnancy only if clearly needed. Non-Teratogenic Effects: Non-Bottalization, respiratory support, and tube feeding. Complications can arise immediately upon delivery. Reports include respiratory distress, cyanosis, panes, seizures, unstable temperature, feeding difficulty, vomiting, hypoplycemia, hypo- and hypertonia, hyperreflexia, termor, ilteriness, inritability, and constant crying. This is consistent with a socie affect of SSIIs or SNISs or a drug discontinuation syndrome. In some cases, it is consistent with a socie affect of SSIIs or SNISs or a drug discontinuation syndrome. In some cases, it is consistent with a vertochloride on labor and delivery in humans is unknown. Nursing Mothers: Venlafazine hydrochloride and DV, tit accite metabolite, are excirted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue Venlafazine bytened Release Tablets, taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness in the pediatric population have not been established [see BOKED WANING and Warrings and Precautions: Clinical Worsening and Suicidas Resk.]. Anyone considering using Venlafazine hydrochloride and adolescents: tubicas upges in Weight and height is exonation by drochloride be addied by the set a pediatric patient with Venlafazine Extended Release Tablets with adverse aneadole tables for the assessed for the assessed for the admetin

To report SUSPECTED ADVERSE REACTIONS, contact Upstate Pharma, LLC Pharmaceutical Corp. at 1-888-299-1053 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This brief summary is based on Venlafaxine Extended Release Tablets Prescribing Information, January 2009. Osmotica Pharmaceutical Corp.

Marketed by Upstate Pharma, LLC, Rochester, NY 14623 for Osmotica Pharmaceutical, Wilmington, NC 28405. ©2009. Osmotica Pharmaceutical Corp., Wilmington, NC 28405. USA TA1047-0309 2F-01/2009

Venlafaxine Extended Release Tablets, a branded alternative for patients with Major Depressive Disorder (MDD)*

EPRESSIO

BUT THE RIGHT TREATMENT MAY MAKE A DIFFERENCE

Venlafaxine Extended Release Tablets: the first and only way to prescribe 225 mg of extended-release, once-daily venlafaxine HCl in a single tablet

- A single 225 mg Venlafaxine Extended Release Tablet vs a combination of venlafaxine HCl extended-release capsules may reduce pill burden for patients taking 225 mg for the treatment of MDD
- Patients with MDD should start treatment with 75 mg/day (in some patients, 37.5 mg/day for 4 to 7 days then increased to 75 mg/day); daily dose can be increased by 75 mg/day at intervals of ≥4 days (maximum 225 mg/day)

For more information, call 1.888.299.1053 or visit www.VERTablets.com

*Venlafaxine Extended Release Tablets are not indicated for the treatment of generalized anxiety disorder or panic disorder

INDICATIONS AND IMPORTANT SAFETY INFORMATION

WARNING: Suicidality and Antidepressants See full Prescribing Information for complete boxed warning.

Increased risk of suicidal thinking and behavior has been reported in children, adolescents and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders. Venlafaxine Extended Release Tablets are not approved for use in pediatric patients.

Venlafaxine Extended Release Tablets (venlafaxine hydrochloride) are indicated for the treatment of Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD). Efficacy of venlafaxine HCl was shown in both short-term trials and a longer-term trial in MDD, and in short-term SAD trials. Venlafaxine Extended Release Tablets are contraindicated in patients taking monoamine oxidase inhibitors (MADIs).

All patients should be monitored appropriately and observed closely for clinical worsening and suicidality, especially at the beginning of drug therapy, or at the time of increases or decreases in dose. Such monitoring should include daily observation by families and caregivers for emergence of agitation, irritability, unusual changes in behavior, or emergence of suicidality.

Venlafaxine Extended Release Tablets should not be used in combination with an MAOI, or within at least 14 days of discontinuing treatment with an MAOI. At least 7 days should be allowed after stopping Venlafaxine Extended Release Tablets before starting an MAOI.

The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SSRIs and SNRIs (including Venlafaxine Extended Release Tablets) alone, but particularly if used concomitantly with serotonergic drugs (including triptans), MA0 inhibitors, or with antipsychotics or other dopamine antagonists. Severe serotonin syndrome can resemble NMS, and patients should be monitored for symptoms of these disorders. If symptoms develop, Venlafaxine Extended Release Tablets and any serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately.

4 WORDS

WRITE IT RIGHT

TABLET

Treatment with venlafaxine hydrochloride is associated with sustained hypertension in some patients. Regular blood pressure monitoring is recommended. Mydriasis has been reported in association with venlafaxine; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma should be monitored.

Dosing must be individualized according to the patient's hepatic and renal function status. Abrupt discontinuation or dose reduction has been associated with discontinuation symptoms (generally self-limiting; serious symptoms possible). A gradual reduction in the dose rather than abrupt cessation is recommended.

After treatment with venlafaxine hydrochloride, insomnia and nervousness, activation of mania/hypomania, symptomatic hyponatremia, seizures, abnormal bleeding (most commonly ecchymosis), dinically relevant increases in serum cholesterol, interstitial lung disease and eosinophilic pneumonia have been reported. Venlafaxime Extended Release Tablets should be used cautiously in patients with a history of seizures. Measurement of serum cholesterol should be considered during long-term treatment. Patients should be cautioned about the risk of bleeding associated with concomitant use of Venlafaxime Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. Venlafaxine Extended Release Tablets should be used during pregnancy and nursing only if clearly needed due to the potential for serious adverse reactions.

Venlafaxine

Extended Release

ablets (VENLAFAXINE HYDROCHLORIDE)

37.5 mg 75 mg 150 mg 225 mg

Adverse reactions occurring in short-term studies of major depressive disorder* were abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, anorexia), CNS complaints (dizziness, somnolence, abnormal dreams) and sweating. Adverse reactions occurring in short-term studies of social anxiety disorder* were asthenia, gastrointestinal complaints (anorexia, dry mouth, nausea), CNS complaints (anxiety, insomnia, libido decreased, nervousness, somnolence, dizziness), abnormalities of sexual function (abnormal ejaculation, orgasmic dysfunction, impotence), yawn, sweating, and abnormal vision.

*Occurring in at least 5% of patients receiving venlafaxine extended release capsules and at a rate at least twice that of placebo.

Please see brief summary of full Prescribing Information, including complete boxed warning, on adjacent pages.

© 2009 Upstate Pharma, LLC All rights reserved. Printed in USA. TA1135-0409

Upstate Pharma, LLC is a wholly owned subsidiary of UCB, Inc.



